0001144204-18-025076.txt : 20180503 0001144204-18-025076.hdr.sgml : 20180503 20180503160219 ACCESSION NUMBER: 0001144204-18-025076 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180503 DATE AS OF CHANGE: 20180503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: APPLIED DNA SCIENCES INC CENTRAL INDEX KEY: 0000744452 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380] IRS NUMBER: 592262718 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36745 FILM NUMBER: 18803671 BUSINESS ADDRESS: STREET 1: 50 HEALTH SCIENCES DRIVE CITY: STONY BROOK STATE: NY ZIP: 11790 BUSINESS PHONE: 631-240-8800 MAIL ADDRESS: STREET 1: 50 HEALTH SCIENCES DRIVE CITY: STONY BROOK STATE: NY ZIP: 11790 FORMER COMPANY: FORMER CONFORMED NAME: PROHEALTH MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 20010504 FORMER COMPANY: FORMER CONFORMED NAME: DCC ACQUISITION CORP DATE OF NAME CHANGE: 19990211 FORMER COMPANY: FORMER CONFORMED NAME: DATALINK CAPITAL CORP/TX/ DATE OF NAME CHANGE: 19980306 10-Q 1 tv492181_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-36745

Applied DNA Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware	59-2262718
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

50 Health Sciences Drive
Stony Brook, New York	11790
(Address of principal executive offices)	(Zip Code)

631-240-8800

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer ¨	Smaller reporting company x
(Do not check if a smaller reporting company)	Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

¨ Yes x No

At April 30, 2018 the registrant had 30,112,057 shares of common stock outstanding.

Applied DNA Sciences, Inc.

Form 10-Q for the Quarter Ended March 31, 2018

Table of Contents

		Page
PART I - FINANCIAL INFORMATION

Item 1 - Condensed Consolidated Financial Statements (unaudited)		3

Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations		17

Item 3 - Quantitative and Qualitative Disclosures About Market Risk		25

Item 4 - Controls and Procedures		26

PART II - OTHER INFORMATION

Item 1 – Legal Proceedings		27

Item 1A – Risk Factors		27

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds		27

Item 3 – Defaults Upon Senior Securities		27

Item 4 – Mine Safety Disclosures		28

Item 5 – Other Information		28

Item 6 – Exhibits		29

Part I - Financial Information

Item 1 - Financial Statements.

APPLIED DNA SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2018			September 30, 2017
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	3,709,402		$	2,959,781
Accounts receivable, net of allowance of $10,000 at March 31, 2018 and September 30, 2017		1,525,715			2,587,969

Inventories		293,838			326,468
Prepaid expenses and other current assets		575,414			366,954
Total current assets		6,104,369			6,241,172

Property and equipment, net		550,907			523,688

Other assets:
Deposits		62,437			61,626

Goodwill		285,386			285,386
Intangible assets, net		930,444			1,042,076

Total Assets	$	7,933,543		$	8,153,948

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable and accrued liabilities	$	1,022,077		$	944,133
Deferred revenue		1,204,351			351,735

Total current liabilities		2,226,428			1,295,868

Commitments and contingencies

Stockholders’ Equity
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of March 31, 2018 and September 30, 2017		—			—
Series A Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of March 31, 2018 and September 30, 2017		—			—
Series B Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of March 31, 2018 and September 30, 2017		—			—
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 30,112,057 and 27,377,057 shares issued and outstanding as of March 31, 2018 and September 30, 2017, respectively		30,112			27,377
Additional paid in capital		247,680,080			243,503,858
Accumulated deficit		(242,003,077	)		(236,673,155	)
Total stockholders’ equity		5,707,115			6,858,080

Total Liabilities and Stockholders’ Equity	$	7,933,543		$	8,153,948

See the accompanying notes to the unaudited condensed consolidated financial statements

APPLIED DNA SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	Three Months Ended March 31,						Six Months Ended March 31,
	2018			2017			2018			2017

Revenues:
Product revenues	$	486,341		$	689,188		$	836,474		$	1,393,605
Service revenues		557,605			216,185			855,149			414,776
Total revenues		1,043,946			905,373			1,691,623			1,808,381

Cost of revenues		372,153			297,372			703,593			572,204

Operating expenses:
Selling, general and administrative		1,996,604			3,230,371			4,589,759			7,131,288
Research and development		669,813			635,893			1,409,880			1,154,521
Depreciation and amortization		145,280			163,368			302,928			325,345

Total operating expenses		2,811,697			4,029,632			6,302,567			8,611,154

LOSS FROM OPERATIONS		(2,139,904	)		(3,421,631	)		(5,314,537	)		(7,374,977	)

Other income (expense):
Interest income, net		-			1,204			-			2,535
Other expense		(6,305	)		(8,429	)		(15,385	)		(17,798	)

Loss before provision for income taxes		(2,146,209	)		(3,428,856	)		(5,329,922	)		(7,390,240	)

Provision for income taxes		—			—			—			—

NET LOSS	$	(2,146,209	)	$	(3,428,856	)	$	(5,329,922	)	$	(7,390,240	)

Net loss per share-basic and diluted	$	(0.07	)	$	(0.13	)	$	(0.18	)	$	(0.29	)

Weighted average shares outstanding-
Basic and diluted		30,112,057			26,351,483			28,879,804			25,886,892

See the accompanying notes to the unaudited condensed consolidated financial statements

APPLIED DNA SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Six Months Ended March 31,
	2018			2017

Cash flows from operating activities:
Net loss	$	(5,329,922	)	$	(7,390,240	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		302,928			325,345
Stock-based compensation		(53,932	)		1,995,924
Provision for bad debts		17,117			21,247
Change in operating assets and liabilities:
Accounts receivable		1,045,136			1,651,510
Inventories		32,630			(55,823	)
Prepaid expenses and other current assets and deposits		(209,269	)		16,658
Accounts payable and accrued liabilities		62,945			(414,822	)
Deferred revenue		852,616			(848,814	)

Net cash used in operating activities		(3,279,751	)		(4,699,015	)

Cash flows from investing activities:

Purchase of property and equipment		(203,516	)		(93,694	)

Net cash used in investing activities		(203,516	)		(93,694	)

Cash flows from financing activities:

Net proceeds from sale of common stock and warrants		4,232,888			4,333,847

Net cash provided by financing activities		4,232,888			4,333,847

Net increase (decrease) in cash and cash equivalents		749,621			(458,862	)
Cash and cash equivalents at beginning of period		2,959,781			4,479,274
Cash and cash equivalents at end of period	$	3,709,402		$	4,020,412

Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest	$	—		$	—
Cash paid during period for income taxes	$	—		$	—

Non-cash investing and financing activities:
Property and equipment acquired, and included in accounts payable	$	15,000		$	60,468

See the accompanying notes to the unaudited condensed consolidated financial statements

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES

General

The accompanying condensed consolidated financial statements as of March 31, 2018 and for the three and six month periods ended March 31, 2018 and 2017 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Regulation S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended March 31, 2018 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2018. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the fiscal year ended September 30, 2017 and footnotes thereto included in the Annual Report on Form 10-K of Applied DNA Sciences, Inc. (the “Company”) filed with the SEC on December 28, 2017.

The condensed consolidated balance sheet as of September 30, 2017 contained herein has been derived from the audited consolidated financial statements as of September 30, 2017, but does not include all disclosures required by GAAP.

Business and Basis of Presentation

The Company is principally devoted to developing and marketing plant-based or other DNA technology solutions in the United States, Europe and Asia. To date, the Company has produced limited recurring revenues from its products and services and has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment and development of a biotechnology company.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc., Applied DNA Sciences Europe Limited, and Applied DNA Sciences India Private Limited. Applied DNA Sciences India Private Limited was incorporated in India on June 22, 2017. Significant inter-company transactions and balances have been eliminated in consolidation.

Inventories

Inventories, which consist primarily of raw materials, and finished goods, is stated at the lower of cost or net realizable value, with cost determined by using the first-in, first-out (FIFO) method.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At March 31, 2018 and September 30, 2017, the Company recorded deferred revenue of $1,204,351 and $351,735, respectively.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Revenue Recognition, continued

Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is available. The applicable revenue recognition criteria are then applied to each of the units.

Revenue for government contract awards, which supports the Company’s development efforts on specific projects, is recognized as firm fixed price government contract awards and are recognized over the period of the contract. The Company recognized revenue from a government contract of $187,010 and $374,020 for the three and six month periods ended March 31, 2018, respectively. The Company did not recognize revenue from government contract awards during the three and six month periods ended March 31, 2017.

The Company has a licensing agreement with a company that operates in the cotton industry. The cotton ginning season in the United States takes place between September and March each year; therefore, revenues from these customer contracts may be seasonal and recognized primarily during the second half of the Company’s fiscal year.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most complex and subjective estimates include recoverability of long-lived assets, fair value calculations for stock based compensation, contingencies, allowance for doubtful accounts and management’s anticipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the condensed consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates.

Income Taxes

The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company estimates the degree to which tax assets and credit carry forwards will result in a benefit based on expected profitability by tax jurisdiction.

In its interim financial statements, the Company follows the guidance in ASC 270, “Interim Reporting” and ASC 740 “Income Taxes”, whereby the Company utilizes the expected annual effective tax rate in determining its income tax provisions for the interim periods. That rate differs from U.S. statutory rates primarily as a result of valuation allowance related to the Company’s net operating loss carryforward as a result of the historical losses of the Company.

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code that will affect the Company’s fiscal year ending September 30, 2018, including, but not limited to, reducing the U.S. federal corporate tax rate. The Tax Act reduces the federal corporate tax rate to 21 percent in the fiscal year ending September 30, 2018. Section 15 of the Internal Revenue Code stipulates that our fiscal year ending September 30, 2018, will have a blended corporate tax rate of approximately 25 percent, which is based on the applicable tax rates before and after the Tax Act and the number of days in the year. The reduction of the corporate tax rate will cause the Company to reduce its deferred tax asset to the lower federal base rate of 21% and adjust the allowance against the deferred tax asset by the same amount. The Company has not yet determined the impact the rate reduction will have on its gross deferred tax asset and liabilities and offsetting valuation allowance. The Company has a full allowance against the deferred tax asset and as a result there was no impact to income tax expense for the three and six month periods ended March 31, 2018.

The changes included in the Tax Act are broad and complex. The final transition impacts of the Tax Act may differ from the above estimate, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the Company has utilized to calculate the transition impact. The Securities Exchange Commission has issued rules that would allow for a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts. We currently anticipate finalizing and recording any resulting adjustments by the end of our current fiscal year ending September 30, 2018.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Net Loss Per Share

The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.

For the three and six month periods ended March 31, 2018 and 2017, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

Securities that could potentially dilute basic net income per share in the future were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive for the three and six month periods ended March 31, 2018 and 2017 are as follows:

	2018		2017

Warrants		12,271,686		9,548,969
Stock options		5,320,308		5,199,477
		17,591,994		14,748,446

Stock-Based Compensation

The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company estimates the number of awards expected to be forfeited and adjusts the estimate when it is no longer probable that the employee will fulfill the service conditions.

The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50.

Concentrations

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

The Company’s revenues earned from sale of products and services for the three month period ended March 31, 2018 included an aggregate of 10%, 12%, 15%, 17% and 22% from five customers, respectively. The Company’s revenues earned from sale of products and services for the six month period ended March 31, 2018 included an aggregate of 11%, 18%, and 28% from three customers, respectively.

The Company’s revenues earned from sale of products and services for the three month period ended March 31, 2017 included 19% and 31% from two customers, respectively. The Company’s revenues earned from sale of products and services for the six month period ended March 31, 2017 included 19% and 41%, from two customers, respectively.

Two customers accounted for 66% and 93% of the Company’s accounts receivable at March 31, 2018 and September 30, 2017, respectively.

Recent Accounting Pronouncements

In July 2017, the Financial Accounting Standards Board (“FASB”) issued a two-part Accounting Standards Update (“ASU”) No. 2017-11, I. Accounting for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception (“ASU 2017-11”). ASU 2017-11 amends guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815, Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company has adopted this guidance for the three and six month periods ended March 31, 2018. The adoption of this pronouncement did not have a material impact on the Company’s condensed consolidated financial statements.

In May 2017, FASB issued ASU 2017-09, Compensation – “Stock Compensation (Topic 718): Scope of Modification Accounting”, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2017. Early adoption is permitted. The Company does not expect the adoption of ASU 2016-09 to have a material impact on its condensed consolidated financial statements and related disclosures.

In January 2017, the FASB ASU 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business” (“ASU 2017-01”). The amendments in this update are to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company is currently evaluating the impact of adopting this guidance.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Recent Accounting Pronouncements, continued

In January 2017, the FASB issued ASU No. 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”). The purpose of the amendment is to simplify how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. For public entities, the amendments in ASU 2017-04 are effective for interim and annual reporting periods beginning after December 15, 2019. The Company is currently assessing the impact of ASU 2017-04 on its condensed consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)." The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The Company is currently evaluating the new guidance to determine the impact it may have on its condensed consolidated financial statements.

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which was subsequently modified in August 2015 by ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2017. The core principle of ASU No. 2014-09 is that companies should recognize revenue when the transfer of promised goods or services to customers occurs in an amount that reflects what the company expects to receive. It requires additional disclosures to describe the nature, amount, timing and uncertainty of revenue and cash flows from contracts with customers. In 2016 and 2017, the FASB issued additional ASUs that clarify the implementation guidance on principal versus agent considerations (ASU 2016-08), on identifying performance obligations and licensing (ASU 2016-10), and on narrow-scope improvements and practical expedients (ASU 2016-12), revenue recognition criteria and other technical corrections (ASU 2016-20) as well as clarifying the scope of asset derecognition guidance and accounting for partial sales of nonfinancial assets (ASU 2017-05). The Company is in the process of evaluating the provisions of these ASU’s and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations. However, based upon the revenue recognized for the current contracts in place as of March 31, 2018, the Company expects to identify similar performance obligations under these ASUs as compared with the deliverables and separate units of accounting previously identified. The Company is also evaluating the transition guidance under ASU 2014-09 to determine if it will apply the full retrospective or modified retrospective approach.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(unaudited)

NOTE B — LIQUIDITY AND MANAGEMENT’S PLAN

The Company has recurring net losses, which have resulted in an accumulated deficit of $242,003,077 as of March 31, 2018. The Company incurred a net loss of $5,329,922 and generated negative operating cash flow of $3,279,751 for the six month period ended March 31, 2018. The Company also had working capital of $3,877,941 and cash and cash equivalents of $3,709,402 as of March 31, 2018. The Company’s current capital resources include cash and cash equivalents, accounts receivable, and inventories. Historically, the Company has financed its operations principally from the sale of equity securities. As discussed in Note E, on December 20, 2017, the Company entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 2,735,000 shares of the Company’s common stock and warrants to purchase an aggregate of 2,735,000 shares of common stock in a registered direct offering with an aggregate gross proceeds of $4,786,250, at a combined purchase price of $1.75 per share for total net proceeds of approximately $4,200,000, after placement agent fees and other estimated offering costs. The offering closed on December 22, 2017.

Management has evaluated relevant conditions and events with respect to liquidity requirements for the twelve month period after the Company’s March 31, 2018 financial statements are filed with the SEC. If the Company does not meet its forecasted revenues for the next twelve months, it would not have sufficient cash and cash equivalents to cover the Company’s operating expenses. Due to this condition, management of the Company has established a plan, which has been approved by its Board of Directors, that includes potential financing options and/or cost saving measures that will be implemented if revenue targets are not met within a specified time period.

Management believes that it is probable that such plan, if implemented, will result in the liquidity deemed necessary for the Company to mitigate the relevant conditions that raised substantial doubt about the Company’s ability to continue as a going concern one year after the date the financial statements are issued.

Management believes that the Company’s cash balances on hand, collection of its accounts receivable, reduced cash burn from cost saving measures and proceeds from a potential financing will be sufficient to fund the Company’s net cash requirements for the next twelve months from the date of filing this quarterly report.

NOTE C — INVENTORIES

Inventories consist of the following:

	March, 2018, 2018		September 30, 2017
	(unaudited)
Raw materials	$	221,383	$	193,069
Finished goods		72,455		133,399
Total	$	293,838	$	326,468

NOTE D — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities are as follows:

	March 31, 2018		September 30, 2017
	(unaudited)
Accounts payable	$	439,212	$	382,984
Accrued salaries payable		472,372		446,012
Other accrued expenses		110,493		115,137
Total	$	1,022,077	$	944,133

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(unaudited)

NOTE E — CAPITAL STOCK

On December 20, 2017, the Company entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,735,000 shares of its common stock and warrants to purchase an aggregate of 2,735,000 shares of common stock in a registered direct offering with aggregate gross proceeds of $4,786,250, at a combined purchase price of $1.75 per share and warrant. The warrants will be immediately exercisable at a price of $2.00 per share of common stock and will expire five years from the date of issuance.

After deducting placement agent fees and other estimated expenses related to the registered direct offering, the aggregate net proceeds were approximately $4,200,000.

The warrants include an adjustment provision that, subject to certain exceptions, reduces their exercise price if the Company issues common stock or common stock equivalents at a price lower than the then-current exercise price of the warrants, subject to a minimum exercise price of $0.44. The exercise price and number of the shares of the Company’s common stock issuable upon the exercise of the warrants will be subject to adjustment as set forth therein (including for stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction). The warrants are subject to a call provision whereby the Company may, subject to certain provisions, including that the weighted average price of the Company’s common stock has exceeded $5.00 for twenty consecutive trading days, call for cancellation of all or any portion of the warrants not yet exercised.

In addition, if and only if there is no effective registration statement registering, or no current prospectus available for, the resale of the warrants, the Purchasers may exercise the warrants by means of a “cashless exercise.”

The offering closed on December 22, 2017.

NOTE F — STOCK OPTIONS AND WARRANTS

Warrants

The following table summarizes the changes in warrants outstanding and the related prices for the shares of common stock issued to non-employees of the Company.

Transactions involving warrants are summarized as follows:

	Number of Shares			Weighted Average Exercise Price Per Share
Balance at October 1, 2017		9,540,455		$	3.60
Granted		2,735,000			2.00
Exercised		-			-
Cancelled or expired		(3,769	)		3.32
Balance at March 31, 2018		12,271,686		$	3.24

Stock Options

In 2005, the Board of Directors and the holders of a majority of the outstanding shares of common stock approved the 2005 Incentive Stock Plan (the “Incentive Plan”). The number of shares of common stock that can be issued as stock awards and stock options thereunder is an aggregate of 8,333,333 shares and the number of shares of common stock that can be covered by awards made to any participant in any calendar year is 833,334 shares. The Incentive Plan’s expiration date is January 25, 2025.

The Incentive Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to the Company's success with an award of options to purchase shares of common stock. As of March 31, 2018, a total of 275,752 shares have been issued and options to purchase 5,842,876 shares have been granted under the Incentive Plan.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(unaudited)

NOTE F — STOCK OPTIONS AND WARRANTS (continued)

Transactions involving stock options issued to employees and consultants are summarized as follows:

	Number of Shares			Weighted Average Exercise Price Per Share			Aggregate Intrinsic Value		Weighted Average Contractual Life (Years)
Outstanding at October 1, 2017		5,333,227		$	3.71
Granted		556,147			1.57
Exercised		-			-
Cancelled or expired		(569,066	)		(3.23	)
Outstanding at March 31, 2018		5,320,308		$	3.53					4.16
Vested at March 31, 2018		4,527,351		$	3.82		$	-		3.84
Non-vested at March 31, 2018		792,957					$	-

During the six month periods ended March 31, 2018, the Company issued stock options to purchase an aggregate of 556,147 shares to non-employee Board of Director members.

The Company uses the Black Scholes Option Pricing Model to determine the fair value of options granted. The following significant weighted average assumptions in the Black Scholes Option Pricing Model were utilized to estimate the fair value of share based payment awards during the six month periods ended March 31, 2018 and 2017:

	Six Month Period Ended March 31, 2018			Six Month Period Ended March 31, 2017
Stock price	$	1.57		$	2.07
Exercise price	$	1.57		$	2.25
Expected term, years		4.87			5.24
Dividend yield		-	%		-	%
Volatility		94	%		112	%
Risk free rate		2.6	%		2.0	%

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(unaudited)

NOTE F — STOCK OPTIONS AND WARRANTS (continued)

The Company recorded a benefit of $285,045 and expense of $537,904 as stock compensation for the three month periods ended March 31, 2018 and 2017, respectively. The Company recorded a benefit of $53,932 and expense of $1,995,924 as stock compensation expense for the six month periods ended March 31, 2018 and 2017, respectively. The benefits during the three and six month periods ended March 31, 2018 are the result of the reversal of the expense of $415,786 previously recorded for certain performance based stock options that were cancelled and therefore the performance conditions were no longer probable and the options did not vest. As of March 31, 2018, unrecorded compensation cost related to non-vested awards was $1,024,483, which is expected to be recognized over a weighted average period of approximately 1.25 years. The weighted average grant date fair value per share for options granted during the six month period ended March 31, 2018 was $1.13.

NOTE G — COMMITMENTS AND CONTINGENCIES

Operating Leases

The Company leases office space under an operating lease in Stony Brook, New York for its corporate headquarters. The lease is for a 30,000 square foot building. The term of the lease commenced on June 15, 2013 and expired on May 31, 2016, with the option to extend the lease for two additional three-year periods. The Company has exercised its option to extend the lease for one additional three-year period ending May 31, 2019. The base rent during the additional three-year period is $458,098 per annum. In addition to the office space, the Company also has 1,500 square feet of laboratory space. The term of the lease commenced on November 1, 2015 and expired on October 31, 2017. Effective November 20, 2017, the Company renewed this lease for one additional year, ending October 31, 2018. The Company set up a satellite testing facility in Ahmedabad, India during fiscal 2017. On November 17, 2017, it leased 1,108 square feet for a three-year term beginning November 1, 2017. The base rent is approximately $6,500 per annum.

Total rent expense for the three and six month periods ended March 31, 2018 were $138,076 and $271,293, respectively. Total rent expense for the three and six month period ended March 31, 2017 were $142,768 and $283,165, respectively.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(unaudited)

NOTE G — COMMITMENTS AND CONTINGENCIES (continued)

Employment Agreement

The Company has an employment agreement with Dr. James Hayward, its Chief Executive Officer effective July 1, 2016. The initial term was through June 30, 2017, with automatic one-year renewal periods. As of June 30, 2017, the employment contract renewed for an additional year. Under the agreement, Dr. Hayward will be eligible for a special cash incentive bonus of up to $800,000, $300,000 of which will be payable if and when annual revenue reaches $8 million and $100,000 of which would be payable for each $2 million of annual revenue in excess of $8 million. Dr Hayward's annual salary under the agreement was $400,000.

Effective May 7, 2016, the Chief Executive Officer's annual salary was voluntarily reduced by $100,000. Effective May 20, 2017, the Chief Executive Officer’s annual salary was voluntarily reduced by an additional $50,000. Accordingly, his current annual base salary as of March 31, 2018 is $250,000. Effective March 15, 2018, the Compensation Committee of the Company’s Board of Directors, approved that the $150,000 reduction in the Chief Executive Officer’s annual salary will be accrued and repaid to the Chief Executive Officer when the Company reaches $3,000,000 in revenues for two consecutive quarters or $12,000,000 in revenues for a fiscal year.

Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time.

NOTE H– GEOGRAPHIC AREA INFORMATION

Net revenues by geographic location of customers are as follows:

Three Month Period Ended March 31,
	2018		2017
United States	$	231,392	$	555,043
Europe		378,834		338,005
Asia and other		433,720		12,325
Total	$	1,043,946	$	905,373

Six Month Period Ended March 31,
	2018		2017
United States	$	524,122	$	1,143,942
Europe		570,662		632,339
Asia and other		596,839		32,100
Total	$	1,691,623	$	1,808,381

Item 2. — Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

This Quarterly Report on Form 10-Q (including but not limited to this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are intended to qualify for the “safe harbor” created by those sections. In addition, we may make forward-looking statements in other documents filed with or furnished to the Securities and Exchange Commission (“SEC”), and our management and other representatives may make forward-looking statement orally or in writing to analysts, investors, representatives of the media and others. Forward-looking statements can generally be identified by the fact that they do not relate strictly to historical or current facts and include, but are not limited to, statements using terminology such as “can”, “may”, “could”, “should”, “assume”, “forecasts”, “believe”, “designated to”, “will”, “expect”, “plan”, “anticipate”, “estimate”, “potential”, “position”, “predicts”, “strategy”, “guidance”, “intend”, “budget”, “seek”, “project” or “continue”, or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future. You should read statements that contain these words carefully because they:

discuss our future expectations;

contain projections of our future results of operations or of our financial condition; and

state other “forward-looking” information.

We believe it is important to communicate our expectations. However, forward-looking statements are based on our current expectations, assumptions, estimates and projections about our business and our industry and are subject to known and unknown risks, uncertainties and other factors. Accordingly, our actual results and the timing of certain events may differ materially from those expressed or implied in such forward-looking statements due to a variety of factors and risks, including, but not limited to, those set forth in this Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our unaudited condensed consolidated financial statements and notes thereto included in this Quarterly Report, those set forth from time to time in our other filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2017, and the following factors and risks:

our lack of significant revenues;

our history of net losses, which may continue, and our potential inability to achieve profitability;

the possibility that we may require additional financing, which may involve the issuance of additional shares of common stock or securities exercisable or convertible into common stock and dilute the percentage of ownership held by our current stockholders;

difficulty in obtaining or inability to obtain, additional financing if such financing becomes necessary;

volatility in the price and/or trading volume of our common stock;

future short selling and/or manipulation of the price of our common stock;

our inability to implement our short and long-term strategies;

competition from products and services provided by other companies;

potential difficulties and failures in manufacturing our products;

loss of strategic relationships;

dependence on a limited number of key customers;

lack of acceptance of our products and services by potential customers;

potential failure to introduce new products and services;

difficulty or failure in expanding/and or maintaining our sales, marketing and support organizations and our distribution arrangements necessary to enable us to reach our goals with respect to increasing market acceptance of our products and services;

seasonality in revenues related to our cotton customer contracts;

shifting enforcement priorities of US federal laws relating to cannabis;

inability to obtain regulatory approval in the pharmaceutical markets;

inability to continue to retain the services of Dr. Hayward, our Chief Executive Officer;

inability to compete effectively in the industries in which we operate;

lack of success in our research and development efforts for new products;

failure to manage our growth in operations and acquisitions of new technologies and businesses;

inability to protect our intellectual property rights;

intellectual property litigation against us or other legal actions or proceedings in which we may become involved;

unauthorized disclosure of sensitive or confidential data (including customer data) and cybersecurity breaches; and

adverse changes in worldwide or domestic economic, political or business conditions.

All forward-looking statements and risk factors included in this Quarterly Report are made as of the date hereof, and all forward-looking statements and risk factors included in documents incorporated herein by reference are made as of their original date, in each case based on information available to us as of the date hereof, or in the case of documents incorporated by reference, the original date of any such document, and we assume no obligations to update any forward-looking statement or risk factor, unless we are required to do so by law. If we do update one or more forward-looking statements, no inference should be drawn that we will make updates with respect to other forward-looking statements or that we will make any further updates to those forward-looking statements at any future time.

Forward-looking statements may include our plans and objectives for future operations, including plans and objectives relating to our products and our future economic performance, projections, business strategy and timing and likelihood of success. Assumptions relating to the forward-looking statements included in this Quarterly Report involve judgments with respect to, among other things, future economic, competitive and market conditions, future business decisions, and the time and money required to successfully complete development and commercialization of our technologies, all of which are difficult or impossible to predict accurately and many of which are beyond our control.

Any of the assumptions underlying the forward-looking statements contained in this Quarterly Report could prove inaccurate and, therefore, we cannot assure you that any of the results or events contemplated in any of such forward-looking statements will be realized. Based on the significant uncertainties inherent in these forward-looking statements, the inclusion of any such statement should not be regarded as a representation or as a guarantee by us that our objectives or plans will be achieved, and we caution you against relying on any of the forward looking-statements contained herein.

Note

Our trademarks in the United States include Applied DNA Sciences^®, SigNature^® molecular tags, SigNature^® T molecular tags, fiberTyping^®, DNAnet^®, digitalDNA^®, SigNify^®, BackTrac^®, Beacon^®and CertainT. All other third-party trademarks, service marks and trade names included or incorporated by reference in this Quarterly Report are the property of their respective owners.

Introduction

Using biotechnology as a forensic foundation, we create unique security solutions addressing the challenges of modern commerce. Whether for supply chain security, brand protection or law enforcement applications, it is our goal to help establish secure flourishing environments that foster quality, integrity and success. With secure taggants, high-resolution DNA authentication, and comprehensive reporting, our SigNature molecular tag technologies are designed to deliver what we believe to be the greatest levels of security, deterrence and legal recourse strength. We are also engaged in the large-scale production of specific linear DNA sequences using the polymerase chain reaction (“PCR”) method for use in diagnostics and therapeutics solutions.

SigNature molecular tags, the core of our technology platform, are what we believe to be nature’s ultimate means of authentication and supply chain security. Our precision-engineered molecular tags have not and, we believe, cannot be broken. Additional layers of protection and complexity are added to the mark in a proprietary manner. SigNature molecular tags in various carriers have proven highly resistant to UV radiation, heat, cold, vibration, abrasion and other extreme environments and conditions. We work closely with our customers to develop solutions that will be optimized to their specifications to deliver maximum impact. Our products and technology are protected by what we believe to be a robust portfolio of patents and trademarks.

Using our tagging products and technology, manufacturers, brands, and other stakeholders can ensure authenticity and protect against diversion throughout a product’s journey from manufacturer to use. Customers using our PCR-produced linear DNA product and services for diagnostics and therapeutic trials receive product made cleaner and faster than historical methods, thereby offering the opportunity for increased efficiency and turnaround times in their processes

The core technologies of our business are supplied as tag, test, and track solutions for supply chains; and as DNA product and services for life sciences applications. Our tag, test and track solutions allow our customers to use molecular tags to mark objects in a unique manner that we believe cannot be replicated, and then identify these objects by detecting the absence or presence of the molecular tag. We believe that our disruptive platform offers broad commercial relevance across many industry verticals. Our underlying strategy in the tagging business is to become a solutions provider for supply chains of process industries in which contracts for our products and services are larger and of longer duration as compared to our historic norms, where the benefits to customers and consumers are more significant, and where our forensic security and traceability offer a unique and protected value. Consumers, governments and companies are demanding details about the systems and sources that deliver their goods. They worry about quality, safety, ethics, and the environmental impact. Farsighted organizations are directly addressing new threats and opportunities presented by this question: Where do these goods come from? These are the questions and concerns we are beginning to address for a growing number of companies. We supply key building blocks for creating secure supply chains with traceability of goods, which in turn can help ensure integrity in supply, honest sales and marketing claims, and ethical and sustainable sourcing.

Our DNA products and services for life sciences applications are used by diagnostics instrument companies to detect specific sequences within biopsy or other samples as an indicator of health problems and in trials by therapeutic and vaccine companies as an integrated piece of their product for resolving health issues. Our strategy is to continue to build our capabilities in DNA production (contract manufacturing), linear DNA design (contract research) and regulatory compliance to grow our value to bio/pharmaceutical companies.

Signature Molecular Tags

SigNature Molecular Tags. The SigNature molecular tag is our patented molecular taggant technology, at the core of our platform. It provides forensic power and protection for a wide array of applications. Highly secure, robust and durable, SigNature molecular tags are an ingredient that can be used to fortify brand protection efforts; strengthen supply chain security; and mark, track and convict criminals. Through our SigNature molecular tags, custom DNA sequences can be embedded into a wide range of host carriers including natural and synthetic fibers, ink, varnish, thread, metal coatings and pharmaceuticals, and nutraceuticals. SigNature molecular tags can be made resistant to challenging environments such as heat, cold, vibration, abrasion, organic solvents, chemicals, UV radiation and other extreme environmental conditions, and so can be identified for numerous years after being embedded directly, or into media applied or attached to the item to be marked. Each individual molecular tag is recorded and stored in a secure database so that we can later detect it using a simple spot test, or the molecular tags can be forensically analyzed in our laboratories to obtain definitive proof of the presence or absence of a specific SigNature molecular tag (e.g., one designed to mark a particular product). Our in-lab forensic testing capability delivers an expert witness Certificate of DNA Authentication (“CODA”). Because DNA is one of the densest information carriers known, and can be amplified with high fidelity, only minute quantities of SigNature molecular tags are necessary for successful analysis and authentication. As a result, SigNature molecular tags can fold seamlessly into production and logistics workflows at extremely low concentrations.

SigNature molecular tags have been subjected to rigorous testing by the Idaho National Laboratory, a U.S. National Laboratory, by CALCE (the Center for Advanced Life Cycle Engineering), the largest electronic products and systems research center focused on electronics reliability, and by verified procedures in our laboratories. The molecular tag has passed all tests across a broad spectrum of materials and substrates, and has met key military stability standards. SigNature molecular tags have also passed a strenuous “red-team” vetting on behalf of the U.S. Defense Logistics Agency.

Hundreds of millions of SigNature molecular tags now exist on items ranging from consumer product packaging to microcircuits to cotton and synthetic fibers; to our knowledge, none has ever been copied.

SigNature T Molecular Tags and fiberTyping

SigNature T Molecular Tags. SigNature T molecular tags are a unique patented tagging and authentication system specifically designed for textiles and apparel. Specially engineered to adhere tenaciously to textile substrates, including natural and synthetic fibers, SigNature T molecular tags are resistant to standard textile production conditions, and cannot be copied. The result: an enduring forensic level molecular tag that remains present from the fiber stage through to the finished product.

Our SigNature T technology allows for better quality control and assurance at any point in the supply chain. SigNature T molecular tags are currently used for brand protection efforts and raw material source compliance programs. For example, American grown cotton fibers can be tagged at the gin in the United States, verified as “American grown” and then traced through every step of the supply chain.

fiberTyping. Our patented cotton genotyping platform, known as “fiberTyping,” described below, complements our SigNature T molecular tag system. fiberTyping is employed to identify the genus and species of the fibers before or after they are tagged with SigNature T molecular tags. fiberTyping cannot be used to provide unique identity or traceability of a specific cotton batch through the supply chain, a function which can only be accomplished by our SigNature T molecular tag system combined with our digital software platform.

fiberTyping is not a molecular tag, but a genotyping test of native cotton fiber DNA, which gives a clear result that determines whether the intended “nature-made” endogenous cotton DNA is present in fiber, yarn or fabric. Samples from the primary material are sent to our forensic labs for DNA analysis and authentication. Cotton classification and the authentication of cotton species after cotton has left its place of origin are issues of global significance, important to brand owners and to governments that must regulate the international cotton trade. The use of endogenous DNA to identify the cotton fiber content in textile supply chains, along with the SigNature T molecular tag system is a significant opportunity for brand license holders to control their intellectual property, for brands to shield themselves against legal liabilities, and for governments to improve their ability to enforce compliance with trade agreements between nations.

We believe that our proprietary DNA extraction protocols and methodologies are more effective than existing forensic systems. We believe that the combination of our SigNatureT molecular tags and fiberTyping solutions cover the forensic authentication market for textiles and that the related protocols we have developed may be applicable to multiple industry verticals, and can mark and authenticate products at every stage of their life cycle, from beginning to end.

DNAnet, Smart DNA and Backtrac

Recognizing that DNA-based evidence is the cornerstone of modern-era law enforcement, we have developed what we believe to be the ultimate crime fighting tools – currently being used in home asset and vehicle marking, as well as commercial applications.

These molecular tags can be used to definitively link evidence and offenders to specific crime scenes. As the crime is investigated, the fluorescing molecular marker can assist police in linking the offender and stolen items to a specific crime scene, creating a greater ability to identify and convict.

These long lasting tagging solutions contain unique molecular tags that can help return stolen or lost property to its rightful owner.

Beacon

Beacon locked optical markers deliver secure real-time inspection capabilities. A unique encrypted mechanism (patent-pending) creates a protected, covert screening tool that can be easily adapted to packaging, security labels and high–value assets through inks, varnishes and coatings. When Beacon locked optical markers are combined with SigNature molecular tags, a strong and flexible end-to-end security solution is created where authenticity and provenance can be determined with confidence.

SigNify

Developing a secure method for real-time, in-field screening of molecularly-tagged items has long been a priority for us. We believe that standard fluorophores, up-converting phosphors, holograms and other more-traditional screening tools provide little to no defense against counterfeiting. We believe that secure in-field inspection backed with forensic-level molecular tag authentication is the key to maintaining a well-defended supply chain or asset management program.

The SigNify IF portable DNA reader provides definitive real-time authentication of SigNature and SigNature T molecular tags in the field. With SigNify IF, Signature molecular tags become a true, front-line solution for supply chain integrity.

Information Technology Systems

Applied DNA Sciences Portal. The CertainT and other customer applications include the use of a software platform that enables customers to manage the security of company-marked goods from point of marking to point of authentication or validation to end of life. The base platform is configurable to customer requirements which differ by vertical market, company business process and IT environment. Basic functions offered include molecular tag inventory management, program training and communications, a database of marked items information, associated documents and images, chain of custody and location tracking, sample authentication processing and CODA downloads, and other administrative functions. Designed for either cloud or local operation, the system supports mobile data capture using bar codes or other technologies. The system is architected as the controller and repository for other validation and authentication devices such as our SigNify DNA Readers, DNA Transfer Systems, and other third party devices and is designed to share data with third party applications through standard interfaces.

DNA Transfer Systems. Our DNA Transfer Systems are developed for DNA marking applications which are high volume with a need for monitoring and control. They are computer based, fully automated, offer remote internet access for real-time monitoring and can be configured for application-specific alerts and reporting online. They were used to mark cotton at seven U.S. cotton gins in the 2017-2018 ginning season and one international location.

CertainT Supply Chain Platform

CertainT helps brands confirm their product’s authenticity and origin with certified, trust, transparency and traceability through the seamless amalgamation of several of our platform technologies to tag, test and track. The CertainT trademark indicates use of the CertainT tagging, testing and tracking platform to enable proof of product claims for any material, item or product. Secure and proven, the CertainT Platform helps manufacturers, brands or other commercial organizations deliver on their promise that customers are buying products that are ethically-sourced, safe and authentic.

Large-scale production of specific DNA sequences using PCR.

Our patented Triathlon™ PCR systems allow for the large-scale production of specific DNA sequences. The systems are computer-controlled, self-contained and modular. DNA sequences produced through the Applied DNA processes and systems are being used by customers as diagnostics and reagents, and provide us the opportunity to cross-sell our DNA-based supply chain security solutions to this installed base and others. We have the ability to manufacture longer DNA sequences valuable in gene therapy, DNA vaccines and diagnostics, with what we believe is a distinct competitive advantage in cost, cleanliness, and time-to-market. These types of DNA are distinct from our DNA security markers and represent a potential new entry into medical markets, where we believe there are opportunities for our broader platform

Plan of Operations

General

To date, the substantial portion of our revenues has been generated from sales of our SigNature and SigNature T molecular tags, our principal supply chain security and product authentication solutions. We expect to grow revenues from sales of our SigNature molecular tags, SigNature T molecular tags, DNAnet, Beacon, SigNify and CertainT offerings as we work with companies and governments to secure supply chains for various types of products and product labeling throughout the world. In addition, we expect to grow revenues from the large-scale production of specific DNA sequences using our Triathlon™ PCR systems which have multiple applications including as a diagnostic and reagent and for gene therapy, DNA vaccines and diagnostics. We also expect to see new revenue in the pharmaceutical and nutraceutical market during the current fiscal year resulting primarily from our agreement with Colorcon, Inc. (“Colorcon”).

We have continued to incur expenses in expanding our business to meet current and anticipated future demand. We have limited sources of liquidity. Our products and services are offered in the United States, Europe and Asia. At the present time, we are focusing our efforts on textile and apparel, pharmaceuticals and nutraceuticals, microcircuits and other electronics, bulk DNA production (for therapeutics, diagnostics and vaccines), cash-in-transit, consumer asset marking, printing and packaging businesses, and agrochemicals. Currently, approximately two-thirds of our annual revenue comes from the cotton textile market. The basic technology we use in various markets is very similar, and we believe our solutions are adaptable for many types of products and markets. In the future, we plan to expand our focus to include additional consumer products, food and beverage and industrial materials. The cotton ginning season in the United States takes place between September and March each year; therefore, revenues from our cotton customer contracts may be seasonal and recognized primarily during the second half of our fiscal year, which may cause our operating results to fluctuate significantly quarterly and annually. For a discussion on seasonality see Note A to the accompanying condensed consolidated financial statements.

Critical Accounting Policies

See Note A to the accompanying unaudited condensed consolidated financial statements for our critical accounting policies.

Comparison of Results of Operations for the Three Month Periods Ended March 31, 2018 and 2017

Revenues

Product revenues

For the three month periods ended March 31, 2018 and 2017, we generated $486,341 and $689,188 in revenues from product sales, respectively. Product revenue decreased by $202,847 or 29% for the three month period ended March 31, 2018 as compared to the same period in the prior fiscal year. This decrease was primarily related to a decrease of approximately $259,000 in textile revenues. The decrease in textile revenue is a result of the recognition of approximately $275,000 of deferred revenue for concentrate previously shipped for the marking of cotton during the three month period ended March 31, 2017.

Service revenues

For the three month periods ended March 31, 2018 and 2017, we generated $557,605 and $216,185 in revenues from sales of services, respectively. Service revenues include our feasibility projects and any research and/or development contracts as well as fiberTyping and authentication services. The increase in service revenues of $341,420 or 158% for the three month period ended March 31, 2018 as compared to the same period in the prior fiscal year is attributable to an increase in revenue from a government contract award of approximately $187,000, as well as an increase in feasibility pilots of approximately $207,000 for a leather industry pilot and a cannabis pilot under our cooperation agreement entered into during January 2018. These increases were offset by a decrease of $45,000 relating to the completion of a feasibility study for fertilizer that matured to commercial supply during the three month period ended March 31, 2018.

Costs and Expenses

Cost of Revenues

Cost of revenues for the three month period ended March 31, 2018 increased by $74,781 or 25% from $297,372 for the three month period ended March 31 2017 to $372,153 for the three month period ended March 31, 2018. Cost of revenues as a percentage of product revenues was 77% and 43% for the three month periods ended March 31, 2018 and 2017, respectively. This increase in cost of revenues as a percentage of product revenues is due to product sales mix, as product sales during the three month period ended March 31, 2017 were primarily comprised of textile sales, which are at a higher gross margin.

Selling, General and Administrative

Selling, general and administrative expenses for the three month period ended March 31, 2018 decreased by $1,233,767 or 38% from $3,230,371 for the three month period ended March 31, 2017 to $1,996,604 for the three month period ended March 31, 2018. The decrease is attributable to an $822,948 decrease in stock compensation, primarily related to certain performance based stock options being cancelled; therefore the performance conditions were no longer probable and the options did not vest during the three month period ended March 31, 2018 and the related expense of $415,786 was reversed. The decrease also relates to operating costs, including payroll, which were allocated to the government development contract award during the three month period ended March 31, 2018 of approximately $86,000 and recorded to research and development expenses. Other decreases were legal costs by approximately $92,000, payroll by an additional $100,000 and advertising and marketing by approximately $55,000.

Research and Development

Research and development expenses increased to $669,813 for the three month period ended March 31, 2018 from $635,893 for the three month period ended March 31, 2017, an increase of $33,920 or 5%. This increase is primarily due to increased development costs incurred in relation to the government development contract award.

Depreciation and Amortization

In the three month period ended March 31, 2018, depreciation and amortization decreased by $18,088 or 11% from $163,368 for the three month period ended March 31, 2017 to $145,280 for the three month period ended March 31, 2018.

Other expense

In the three month period ended March 31, 2018, total other expense decreased by $2,124 from expense of $8,429 for the three month period ended March 31, 2017 to expense of $6,305 for the three month period ended March 31, 2018.

Net Loss

Net loss decreased by $1,282,647 or 37% from a loss of $3,428,856 for the three month period ended March 31, 2017 to a loss of $2,146,209 for the three month period ended March 31, 2018, due to the factors noted above.

Comparison of Results of Operations for the Six Month Periods Ended March 31, 2018 and 2017

Revenues

Product revenues

For the six month periods ended March 31, 2018 and 2017, we generated $836,474 and $1,393,605 in revenues from product sales, respectively. Product revenue decreased by $557,131 or 40% for the six month period ended March 31, 2018 as compared to the six month period ended March 31, 2017. Product revenues decreased approximately $485,000 as a result of cotton textile revenues. The decrease in cotton textile revenue is due to the recognition of approximately $275,000 of deferred revenue for concentrate previously shipped for the marking of cotton as well as concentrate sold for the marking of organic cotton of approximately $155,000 during the six month period ended March 31, 2017.

Service revenues

For the six month periods ended March 31, 2018 and 2017, we generated $855,149 and $414,776 in revenues from sales of services, respectively. The increase in service revenues of $440,373 or 106% for the six month period ended March 31, 2018 as compared to the six month period ended March 31, 2017 is attributable to an increase in revenue from the government contract award of approximately $374,000, an increase in feasibility pilots of $125,000 for textiles and an increase of $105,000 for the cannabis feasibility project under the cooperation agreement entered into during January 2018. These increases were offset by a decrease relating to the completion of a feasibility study for fertilizer that matured to commercial supply during the six month period ended March 31, 2018.

Costs and Expenses

Cost of Revenues

Cost of revenues for the six month period ended March 30, 2018 increased by $131,389 or 23% from $572,204 for the six month period ended March 31, 2017 to $703,593 for the six month period ended March 31, 2018. Cost of revenues as a percentage of product revenues was 84% and 41% for the six month periods ended March 31, 2018 and 2017, respectively. This increase in cost of revenues as a percentage of product revenues is due to product sales mix, as sales during the six month period ended March 31, 2017 were primarily comprised of textile sales, which are at a higher gross margin.

Selling, General and Administrative

Selling, general and administrative expenses for the six month period ended March 31, 2018 decreased by 2,541,529 or 36% from $7,131,288 for the six month period ended March 31, 2017 to $4,589,759 for the six month period ended March 31, 2018. The decrease is attributable to a decrease in stock based compensation expense of approximately $2,050,000, primarily associated with stock option grants during the six month period ended March 31, 2017, which vested immediately and also as a result of certain performance based stock options being cancelled; therefore the performance conditions were no longer probable and the options did not vest during the six months ended March 31, 2018 and the related expense of $415,786 was reversed. Further, selling, general and administrative expenses decreased by approximately $105,000 in advertising and marketing and $172,000 in professional fees. The decrease also relates to operating costs, including payroll, which were allocated to the government development contract award during the six month period ended March 31, 2018 of approximately $150,000, which were recorded to research and development.

Research and Development

Research and development expenses increased to $1,409,880 for the six month period ended March 31, 2018 from $1,154,521 for the six month period ended March 31, 2017, an increase of $255,359 or 22%. This increase is primarily due to increased development costs incurred in relation to the government development contract award.

Depreciation and Amortization

In the six month period ended March 31, 2018, depreciation and amortization decreased by $22,417 or 7% from $325,345 for the six month period ended March 31, 2017 to $302,928 for the six month period ended March 31, 2018.

Other expense

In the six month period ended March 31, 2018, total other expense decreased by $2,413 from expense of $17,798 for the six month period ended March 31, 2017 to expense of $15,385 for the six month period ended March 31, 2018.

Net Loss

Net loss decreased by $2,060,318 or 28% from $7,390,240 for the six month period ended March 31, 2017 to $5,329,922 for the six month period ended March 31, 2018, due to the factors noted above.

Liquidity and Capital Resources

Our liquidity needs consist of our working capital requirements and research and development expenditure funding. As of March 31, 2018, we had working capital of $3,877,941. For the six month period ended March 31, 2018, we generated a net cash flow deficit from operating activities of $3,279,751 consisting primarily of our loss of $5,329,922 net with non-cash adjustments of $302,928 in depreciation and amortization charges, a benefit of $53,932 for stock-based compensation and $17,117 of bad debt expense. Additionally, we had a net decrease in operating assets of $868,497 and a net increase in operating liabilities of $915,561. Cash used in investing activities was $203,516 for the purchase of property and equipment. Cash provided by financing activities was $4,232,888 consisting primarily of net proceeds from the December 2017 securities purchase agreement.

We have recurring net losses, which have resulted in an accumulated deficit of $242,003,077 as of March 31, 2018. We have incurred a net loss of $5,329,922, for the six month period ended March 31, 2018. At March 31, 2018 we had cash and cash equivalents of $3,709,402. Our current capital resources include cash and cash equivalents, accounts receivable, and inventories. Historically, we have financed our operations principally from the sale of equity securities. As disclosed in Note E to the accompanying condensed consolidated financial statements, on December 22, 2017, we closed on a securities purchase agreement with certain institutional investors for the purchase and sale of 2,735,000 shares of our common stock and warrants to purchase an aggregate of 2,735,000 shares of common stock in a registered direct offering with aggregate gross proceeds of $4,786,250 exclusive of warrant exercise proceeds. After deducting placement agent’s commissions and other offering expenses total net proceeds were approximately $4,200,000.

Management has evaluated relevant conditions and events with respect to liquidity requirements for the twelve month period after the Company’s March 31, 2018 financial statements are filed with the SEC. If the Company does not meet its forecasted revenues for the next twelve months, it would not have sufficient cash and cash equivalents to cover the Company’s operating expenses. Due to this condition, management of the Company has established a plan, which has been approved by its Board of Directors that includes potential financing options and/or cost saving measures that will be implemented if revenue targets are not met within a specified time period.

Management believes that it is probable that such plans, if implemented, will result in the liquidity deemed necessary for the Company to mitigate the relevant conditions that raised substantial doubt about the Company’s ability to continue as a going concern one year after the date the financial statements are issued.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Inflation

The effect of inflation on our revenue and operating results was not significant.

Item 3. — Quantitative and Qualitative Disclosures About Market Risk.

Information requested by this Item is not applicable as we are electing scaled disclosure requirements available to smaller reporting companies with respect to this Item.

Item 4. — Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we conducted an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on the evaluation of these disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2018, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended March 31, 2018, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II — Other Information

Item 1. — Legal Proceedings.

None.

Item 1A. — Risk Factors.

You should carefully consider the risks and uncertainties described under the caption “Forward-Looking Statements” in Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of this Quarterly Report and in our other filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2017, and our subsequent filings. The risks and uncertainties described in this Quarterly Report and in our other filings with the SEC are not the only ones facing us. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may also affect us. If any of these risks actually materialize, our business, financial position, results of operations and cash flows could be materially adversely impacted. In that event, the market price of our common stock could decline and you may lose all or part of your investment. As further described under the caption “Forward-Looking Statements” in Part I, Item 2, this Quarterly Report also contains forward-looking statements that involve additional risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements due to the factors and risks described above or other factors.

During the fiscal quarter ended March 31, 2018, there have been no material changes in our risk factors previously disclosed under Part 1, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2017 other than as described below.

Shifting enforcement priorities of US federal laws relating to cannabis

The Company is currently developing supply chain solutions for the cannabis industry. These solutions are intended to verify the authenticity, origin and provenance of cannabis. Cannabis is a Schedule I substance as defined under U.S. federal law, and its possession and use is generally not permitted under U.S. federal law, although a number of individual states have enacted state laws to authorize possession, sale and use of cannabis for medical purposes, and in some states for recreational purposes. Our solutions will be utilized in those U.S. states where cannabis possession, sale and/or use is legal under state law. While our cannabis supply chain solutions are distinct from cannabis itself, our cannabis supply chain business and related revenue may nevertheless be adversely impacted by such laws at the federal and/or state level in the United States, or potentially in foreign jurisdictions. It is possible that such laws may result in our cannabis supply chain business having no revenues.

Pharmaceutical related revenue is generally dependent on regulatory approval, oversight and/or compliance.

The sale and use of our products and services in the pharmaceutical market will generally be subject to regulatory approval and/or oversight, potentially including approval and/or oversight in various foreign jurisdictions. Our pharmaceutical products and services will be incorporated into products that cannot be marketed in the United States or in many other jurisdictions without approval by the Food and Drug Administration (FDA) or comparable agencies of other countries or regions. Obtaining such regulatory approvals is costly, time-consuming, uncertain, and subject to unanticipated delays. When, if ever, such approvals will be obtained is unknown. Our revenue in the pharmaceutical market, including revenue from our agreements with Colorcon is highly dependent upon obtaining such approval.

Federal agencies, including the FDA and Federal Trade Commission (FTC), as well as state, local, and foreign authorities, also exercise ongoing review and control of the manufacturing, packaging, labeling, advertising, sale, distribution, and monitoring of pharmaceutical products. Failure to comply with any of these regulations or other requirements could also have an adverse effect on our revenue in the pharmaceutical market.

Item 2. — Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. — Defaults Upon Senior Securities.

None.

Item 4. — Mine Safety Disclosures.

None.

Item 5. — Other Information.

Effective May 7, 2016, the Chief Executive Officer's annual salary was voluntarily reduced by $100,000. Effective May 20, 2017, the Chief Executive Officer’s annual salary was voluntarily reduced by an additional $50,000. Accordingly, his current annual base salary as of March 31, 2018 is $250,000. Effective March 15, 2018, the Compensation Committee of the Company’s Board of Directors approved that the $150,000 reduction in the Chief Executive Officer’s annual salary will be accrued and repaid to the Chief Executive Officer when the Company reaches $3,000,000 in revenues for two consecutive quarters or $12,000,000 in revenues for a fiscal year.

Item 6. — Exhibits.

31.1*	Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended

31.2*	Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended

32.1**	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)

32.2**	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)

101 INS*	XBRL Instance Document

101 SCH*	XBRL Taxonomy Extension Schema Document

101 CAL*	XBRL Taxonomy Extension Calculation Linkbase Document

101 DEF*	XBRL Taxonomy Extension Definition Linkbase Document

101 LAB*	XBRL Extension Label Linkbase Document

101 PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** Furnished herewith.

Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Applied DNA Sciences, Inc.

Dated: May 3, 2018	/s/ JAMES A. HAYWARD
	James A. Hayward, Ph. D.
	Chief Executive Officer
	(Duly authorized officer and principal executive officer)

	/s/ BETH JANTZEN
Dated: May 3, 2018	Beth Jantzen, CPA
	Chief Financial Officer
	(Duly authorized officer and
	principal financial and accounting officer)

EX-31.1 2 tv492181_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13 a -14(a) OR 15 d -14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, James A. Hayward, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Applied DNA Sciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 3, 2018

	By:	/s/ JAMES A. HAYWARD
		James A. Hayward
		Chief Executive Officer
		Applied DNA Sciences, Inc.

EX-31.2 3 tv492181_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13 a -14(a) OR 15 d -14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Beth Jantzen, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Applied DNA Sciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 3, 2018

	By:	/s/ BETH JANTZEN
		Beth Jantzen, CPA
		Chief Financial Officer
		Applied DNA Sciences, Inc.

EX-32.1 4 tv492181_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, James A. Hayward, Chief Executive Officer of Applied DNA Sciences, Inc. (the “Company”), in connection with the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2018 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, hereby certifies pursuant to the requirements of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that

●	the Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934, and

●	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.

	By:	/s/ JAMES A. HAYWARD
		James A. Hayward
		Chief Executive Officer
		Applied DNA Sciences, Inc.
		Dated: May 3, 2018

EX-32.2 5 tv492181_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Beth Jantzen, Chief Financial Officer of Applied DNA Sciences, Inc. (the “Company”), in connection with the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2018 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, hereby certifies pursuant to the requirements of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that

●	the Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934, and

●	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.

	By:	/s/ BETH JANTZEN
		Beth Jantzen, CPA
		Chief Financial Officer
		Applied DNA Sciences, Inc.
		Dated: May 3, 2018

EX-101.INS 6 apdn-20180331.xml XBRL INSTANCE DOCUMENT 0000744452 2013-06-01 2013-06-15 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:EmploymentAgreementMember 2016-05-07 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:NewEmploymentAgreementMember 2016-07-01 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:NewEmploymentAgreementMember 2016-06-02 2016-07-01 0000744452 2017-01-01 2017-03-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:SecondCustomerMember 2017-01-01 2017-03-31 0000744452 country:US 2017-01-01 2017-03-31 0000744452 us-gaap:EuropeMember 2017-01-01 2017-03-31 0000744452 apdn:AsiaAndOtherMember 2017-01-01 2017-03-31 0000744452 us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-03-31 0000744452 2016-10-01 2017-03-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:SecondCustomerMember 2016-10-01 2017-03-31 0000744452 country:US 2016-10-01 2017-03-31 0000744452 us-gaap:EuropeMember 2016-10-01 2017-03-31 0000744452 apdn:AsiaAndOtherMember 2016-10-01 2017-03-31 0000744452 us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2016-10-01 2017-03-31 0000744452 us-gaap:WarrantMember 2016-10-01 2017-03-31 0000744452 us-gaap:EmployeeStockOptionMember 2016-10-01 2017-03-31 0000744452 2017-03-31 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:EmploymentAgreementMember 2017-05-20 0000744452 2017-09-30 0000744452 us-gaap:SeriesAPreferredStockMember 2017-09-30 0000744452 us-gaap:SeriesBPreferredStockMember 2017-09-30 0000744452 2017-11-01 2017-11-17 0000744452 apdn:SecuritiesPurchaseAgreementMember us-gaap:PrivatePlacementMember 2017-12-20 0000744452 2017-12-01 2017-12-20 0000744452 apdn:SecuritiesPurchaseAgreementMember us-gaap:PrivatePlacementMember 2017-12-01 2017-12-20 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:EmploymentAgreementMember 2018-03-15 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:EmploymentAgreementMember 2018-03-01 2018-03-15 0000744452 2018-01-01 2018-03-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:SecondCustomerMember 2018-01-01 2018-03-31 0000744452 country:US 2018-01-01 2018-03-31 0000744452 us-gaap:EuropeMember 2018-01-01 2018-03-31 0000744452 apdn:AsiaAndOtherMember 2018-01-01 2018-03-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:FirstCustomerMember 2018-01-01 2018-03-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:ThirdCustomerMember 2018-01-01 2018-03-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:FourthCustomerMember 2018-01-01 2018-03-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:FifthCustomerMember 2018-01-01 2018-03-31 0000744452 2017-10-01 2018-03-31 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:EmploymentAgreementMember 2017-10-01 2018-03-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:SecondCustomerMember 2017-10-01 2018-03-31 0000744452 country:US 2017-10-01 2018-03-31 0000744452 us-gaap:EuropeMember 2017-10-01 2018-03-31 0000744452 apdn:AsiaAndOtherMember 2017-10-01 2018-03-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:FirstCustomerMember 2017-10-01 2018-03-31 0000744452 us-gaap:WarrantMember 2017-10-01 2018-03-31 0000744452 us-gaap:EmployeeStockOptionMember 2017-10-01 2018-03-31 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2017-10-01 2018-03-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:ThirdCustomerMember 2017-10-01 2018-03-31 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember apdn:TwoCustomersMember 2017-10-01 2018-03-31 0000744452 2018-03-31 0000744452 us-gaap:SeriesAPreferredStockMember 2018-03-31 0000744452 us-gaap:SeriesBPreferredStockMember 2018-03-31 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2018-03-31 0000744452 2018-04-30 0000744452 2016-09-30 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2017-09-30 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure apdn:Customer utr:sqft APPLIED DNA SCIENCES INC 0000744452 apdn --09-30 Smaller Reporting Company 30112057 10-Q 2018-03-31 false 2018 Q2

4020412

2959781

3709402

4479274

2587969

1525715

326468

293838

366954

575414

6241172

6104369

523688

550907

61626

62437

285386

1042076

930444

8153948

7933543

944133

1022077

351735

1204351

1295868

2226428

27377

30112

243503858

247680080

-236673155

-242003077

6858080

5707115

8153948

7933543

10000

0.001

10000000

0.001

500000000

27377057

30112057

27377057

30112057

689188

1393605

486341

836474

216185

414776

557605

855149

905373

555043

338005

12325

1808381

1143942

632339

32100

1043946

231392

378834

433720

1691623

524122

570662

596839

297372

572204

372153

703593

3230371

7131288

1996604

4589759

635893

1154521

669813

1409880

163368

325345

145280

302928

4029632

8611154

2811697

6302567

-3421631

-7374977

-2139904

-5314537

1204

2535

-8429

-17798

-6305

-15385

-3428856

-7390240

-2146209

-5329922

-3428856

-7390240

-2146209

-5329922

-0.13

-0.29

-0.07

-0.18

26351483

25886892

30112057

28879804

325345

302928

-537904

1995924

-1995924

285045

-53932

53932

21247

17117

-1651510

-1045136

55823

-32630

-16658

209269

-414822

62945

-848814

852616

-4699015

-3279751

93694

203516

-93694

-203516

4333847 4232888

4333847

4232888

-458862

749621

60468 15000

<div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>NOTE A — SUMMARY OF ACCOUNTING POLICIES</b> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>General</u></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The accompanying condensed consolidated financial statements as of March 31, 2018 and for the three and six month periods ended March 31, 2018 and 2017 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Regulation S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended March 31, 2018 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2018. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the fiscal year ended September 30, 2017 and footnotes thereto included in the Annual Report on Form 10-K of Applied DNA Sciences, Inc. (the “Company”) filed with the SEC on December 28, 2017.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The condensed consolidated balance sheet as of September 30, 2017 contained herein has been derived from the audited consolidated financial statements as of September 30, 2017, but does not include all disclosures required by GAAP.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Business and Basis of Presentation</u></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company is principally devoted to developing and marketing plant-based or other DNA technology solutions in the United States, Europe and Asia. To date, the Company has produced limited recurring revenues from its products and services and has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment and development of a biotechnology company.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc., Applied DNA Sciences Europe Limited, and Applied DNA Sciences India Private Limited. Applied DNA Sciences India Private Limited was incorporated in India on June 22, 2017. Significant inter-company transactions and balances have been eliminated in consolidation. </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Inventories</u></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Inventories, which consist primarily of raw materials, and finished goods, is stated at the lower of cost or net realizable value, with cost determined by using the first-in, first-out (FIFO) method.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Revenue Recognition</u></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At March 31, 2018 and September 30, 2017, the Company recorded deferred revenue of $1,204,351 and $351,735, respectively.</p> <div style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </div> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </div> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is available. The applicable revenue recognition criteria are then applied to each of the units.</div> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Revenue for government contract awards, which supports the Company’s development efforts on specific projects, is recognized as firm fixed price government contract awards and are recognized over the period of the contract. The Company recognized revenue from a government contract of $187,010 and $374,020 for the three and six month periods ended March 31, 2018, respectively. The Company did not recognize revenue from government contract awards during the three and six month periods ended March 31, 2017.</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company has a licensing agreement with a company that operates in the cotton industry. The cotton ginning season in the United States takes place between September and March each year; therefore, revenues from these customer contracts may be seasonal and recognized primarily during the second half of the Company’s fiscal year.<b>  </b><b>  </b></div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u></u> </p> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Use of Estimates</u></div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most complex and subjective estimates include recoverability of long-lived assets, fair value calculations for stock based compensation, contingencies, allowance for doubtful accounts and management’s anticipated liquidity. Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the condensed consolidated financial statements in the period they are deemed necessary. Accordingly, actual results could differ from those estimates. </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Income Taxes</u></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company estimates the degree to which tax assets and credit carry forwards will result in a benefit based on expected profitability by tax jurisdiction.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In its interim financial statements, the Company follows the guidance in ASC 270, “Interim Reporting” and ASC 740 “Income Taxes”, whereby the Company utilizes the expected annual effective tax rate in determining its income tax provisions for the interim periods. That rate differs from U.S. statutory rates primarily as a result of valuation allowance related to the Company’s net operating loss carryforward as a result of the historical losses of the Company.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code that will affect the Company’s fiscal year ending September 30, 2018, including, but not limited to, reducing the U.S. federal corporate tax rate.  The Tax Act reduces the federal corporate tax rate to 21 percent in the fiscal year ending September 30, 2018.  Section 15 of the Internal Revenue Code stipulates that our fiscal year ending September 30, 2018, will have a blended corporate tax rate of approximately 25 percent, which is based on the applicable tax rates before and after the Tax Act and the number of days in the year.  The reduction of the corporate tax rate will cause the Company to reduce its deferred tax asset to the lower federal base rate of 21% and adjust the allowance against the deferred tax asset by the same amount. The Company has not yet determined the impact the rate reduction will have on its gross deferred tax asset and liabilities and offsetting valuation allowance. The Company has a full allowance against the deferred tax asset and as a result there was no impact to income tax expense for the three and six month periods ended March 31, 2018.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The changes included in the Tax Act are broad and complex. The final transition impacts of the Tax Act may differ from the above estimate, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the Company has utilized to calculate the transition impact. The Securities Exchange Commission has issued rules that would allow for a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts. We currently anticipate finalizing and recording any resulting adjustments by the end of our current fiscal year ending September 30, 2018.</p> <div style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Net Loss Per Share</u></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">For the three and six month periods ended March 31, 2018 and 2017, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Securities that could potentially dilute basic net income per share in the future were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive for the three and six month periods ended March 31, 2018 and 2017 are as follows: </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2018</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-left: 0in; width: 933px;">Warrants</td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;"> </td> <td style="text-align: right; width: 96px;">12,271,686</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;"> </td> <td style="text-align: right; width: 95px;">9,548,969</td> <td style="text-align: left; width: 11px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Stock options</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">5,320,308</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">5,199,477</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-bottom: 1pt; text-indent: -2in; padding-left: 2in;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">17,591,994</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">14,748,446</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Stock-Based Compensation</u></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified as cash flows from operating activities. All excess tax benefits and tax deficiencies (including tax benefits of dividends on share-based payment awards) are recognized as income tax expense or benefit in the condensed consolidated statements of operations. The Company estimates the number of awards expected to be forfeited and adjusts the estimate when it is no longer probable that the employee will fulfill the service conditions.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company accounts for stock-based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">  </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Concentrations</u></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and cash equivalents with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. </p> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company’s revenues earned from sale of products and services for the three month period ended March 31, 2018 included an aggregate of 10%, 12%, 15%, 17% and 22% from five customers, respectively. The Company’s revenues earned from sale of products and services for the six month period ended March 31, 2018 included an aggregate of 11%, 18%, and 28% from three customers, respectively.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company’s revenues earned from sale of products and services for the three month period ended March 31, 2017 included 19% and 31% from two customers, respectively. The Company’s revenues earned from sale of products and services for the six month period ended March 31, 2017 included 19% and 41%, from two customers, respectively. </div> <div style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </div> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Two customers accounted for 66% and 93% of the Company’s accounts receivable at March 31, 2018 and September 30, 2017, respectively.</div> <p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Recent Accounting Pronouncements</u></p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b> </b> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In July 2017, the Financial Accounting Standards Board (“FASB”) issued a two-part Accounting Standards Update (“ASU”) No. 2017-11, I. Accounting for Certain Financial Instruments With Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception (“ASU 2017-11”). ASU 2017-11 amends guidance in FASB ASC 260, Earnings Per Share, FASB ASC 480, Distinguishing Liabilities from Equity, and FASB ASC 815, Derivatives and Hedging. The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. ASU 2017-11 is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company has adopted this guidance for the three and six month periods ended March 31, 2018. The adoption of this pronouncement did not have a material impact on the Company’s condensed consolidated financial statements.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In May 2017, FASB issued ASU 2017-09, Compensation – “Stock Compensation (Topic 718): Scope of Modification Accounting”<i>,</i> which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2017. Early adoption is permitted. The Company does not expect the adoption of ASU 2016-09 to have a material impact on its condensed consolidated financial statements and related disclosures.</div> <div style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </div> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> In January 2017, the FASB ASU 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business” (“ASU 2017-01”). The amendments in this update are to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and consolidation. The guidance is effective for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company is currently evaluating the impact of adopting this guidance.</div> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">   </div> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> In January 2017, the FASB issued ASU No. 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”). The purpose of the amendment is to simplify how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. For public entities, the amendments in ASU 2017-04 are effective for interim and annual reporting periods beginning after December 15, 2019. The Company is currently assessing the impact of ASU 2017-04 on its condensed consolidated financial statements.</div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)." The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The Company is currently evaluating the new guidance to determine the impact it may have on its condensed consolidated financial statements.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”), which was subsequently modified in August 2015 by ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2017. The core principle of ASU No. 2014-09 is that companies should recognize revenue when the transfer of promised goods or services to customers occurs in an amount that reflects what the company expects to receive. It requires additional disclosures to describe the nature, amount, timing and uncertainty of revenue and cash flows from contracts with customers. In 2016 and 2017, the FASB issued additional ASUs that clarify the implementation guidance on principal versus agent considerations (ASU 2016-08), on identifying performance obligations and licensing (ASU 2016-10), and on narrow-scope improvements and practical expedients (ASU 2016-12), revenue recognition criteria and other technical corrections (ASU 2016-20) as well as clarifying the scope of asset derecognition guidance and accounting for partial sales of nonfinancial assets (ASU 2017-05). The Company is in the process of evaluating the provisions of these ASU’s and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations. However, based upon the revenue recognized for the current contracts in place as of March 31, 2018, the Company expects to identify similar performance obligations under these ASUs as compared with the deliverables and separate units of accounting previously identified. The Company is also evaluating the transition guidance under ASU 2014-09 to determine if it will apply the full retrospective or modified retrospective approach.</div> </div>

<div> <div style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>NOTE D — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</b></div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Accounts payable and accrued liabilities are as follows:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"></p> <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>March 31,<br />2018</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>September 30, <br />2017</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 5.4pt;"><b> </b></td> <td><b> </b></td> <td style="text-align: center;" colspan="2"><font style="font-size: 10pt;"><b> (unaudited)</b></font></td> <td style="text-align: left;"><b> </b></td> <td><b> </b></td> <td style="text-align: left;"><b> </b></td> <td style="text-align: right;"><b> </b></td> <td style="text-align: left;"><b> </b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0in; width: 933px;">Accounts payable</td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 96px;">439,212</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 95px;">382,984</td> <td style="text-align: left; width: 11px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0in;">Accrued salaries payable</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">472,372</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">446,012</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Other accrued expenses</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">110,493</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">115,137</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Total</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">1,022,077</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">944,133</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table> </div>

<div> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>NOTE E — CAPITAL STOCK</b></div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On December 20, 2017, the Company entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,735,000 shares of its common stock and warrants to purchase an aggregate of 2,735,000 shares of common stock in a registered direct offering with aggregate gross proceeds of $4,786,250, at a combined purchase price of $1.75 per share and warrant. The warrants will be immediately exercisable at a price of $2.00 per share of common stock and will expire five years from the date of issuance.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">After deducting placement agent fees and other estimated expenses related to the registered direct offering, the aggregate net proceeds were approximately $4,200,000.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The warrants include an adjustment provision that, subject to certain exceptions, reduces their exercise price if the Company issues common stock or common stock equivalents at a price lower than the then-current exercise price of the warrants, subject to a minimum exercise price of $0.44. The exercise price and number of the shares of the Company’s common stock issuable upon the exercise of the warrants will be subject to adjustment as set forth therein (including for stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction). The warrants are subject to a call provision whereby the Company may, subject to certain provisions, including that the weighted average price of the Company’s common stock has exceeded $5.00 for twenty consecutive trading days, call for cancellation of all or any portion of the warrants not yet exercised.  </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In addition, if and only if there is no effective registration statement registering, or no current prospectus available for, the resale of the warrants, the Purchasers may exercise the warrants by means of a “cashless exercise.”</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The offering closed on December 22, 2017.</div> </div>

<p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>NOTE F — STOCK OPTIONS AND WARRANTS</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Warrants</u></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The following table summarizes the changes in warrants outstanding and the related prices for the shares of common stock issued to non-employees of the Company.</p> <p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b> </b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Transactions involving warrants are summarized as follows:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Number of <br />Shares</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Weighted <br />Average <br />Exercise <br />Price Per <br />Share</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-left: 0in; width: 933px;">Balance at October 1, 2017</td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;"> </td> <td style="text-align: right; width: 96px;">9,540,455</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 95px;">3.60</td> <td style="text-align: left; width: 11px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 0in;">Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,735,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.00</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-left: 0in;">Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Cancelled or expired</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(3,769</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">3.32</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Balance at March 31, 2018</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">12,271,686</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">3.24</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Stock Options</u></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In 2005, the Board of Directors and the holders of a majority of the outstanding shares of common stock approved the 2005 Incentive Stock Plan (the “Incentive Plan”). The number of shares of common stock that can be issued as stock awards and stock options thereunder is an aggregate of 8,333,333 shares and the number of shares of common stock that can be covered by awards made to any participant in any calendar year is 833,334 shares. The Incentive Plan’s expiration date is January 25, 2025.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Incentive Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to the Company's success with an award of options to purchase shares of common stock. As of March 31, 2018, a total of 275,752 shares have been issued and options to purchase 5,842,876 shares have been granted under the Incentive Plan.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Transactions involving stock options issued to employees and consultants are summarized as follows:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 85%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Number of <br />Shares</b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Weighted <br />Average <br />Exercise <br />Price Per <br />Share</b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Aggregate <br />Intrinsic <br />Value</b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Weighted Average Contractual Life<br />(Years)</b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="width: 680px;">Outstanding at October 1, 2017</td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 13px;"> </td> <td style="text-align: right; width: 104px;">5,333,227</td> <td style="text-align: left; width: 13px;"> </td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 103px;">3.71</td> <td style="text-align: left; width: 13px;"> </td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 13px;"> </td> <td style="text-align: right; width: 104px;"> </td> <td style="text-align: left; width: 13px;"> </td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 18px;"> </td> <td style="text-align: right; width: 184px;"> </td> <td style="text-align: left; width: 13px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">556,147</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.57</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td>Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Cancelled or expired</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(569,066</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(3.23</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td>Outstanding at March 31, 2018</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5,320,308</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">3.53</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center; vertical-align: bottom;">4.16</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Vested at March 31, 2018</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">4,527,351</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;">$</td> <td style="text-align: right; padding-bottom: 1pt;">3.82</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom;">3.84</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Non-vested at March 31, 2018</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">792,957</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">During the six month periods ended March 31, 2018, the Company issued stock options to purchase an aggregate of 556,147 shares to non-employee Board of Director members.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company uses the Black Scholes Option Pricing Model to determine the fair value of options granted. The following significant weighted average assumptions in the Black Scholes Option Pricing Model were utilized to estimate the fair value of share based payment awards during the six month periods ended March 31, 2018 and 2017: </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="white-space: nowrap;" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt; white-space: nowrap;" nowrap="nowrap"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center; white-space: nowrap;" colspan="2" nowrap="nowrap"><b>Six Month <br />Period Ended <br />March 31, 2018</b></td> <td style="padding-bottom: 1pt; white-space: nowrap;" nowrap="nowrap"><b> </b></td> <td nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; white-space: nowrap;" colspan="2" nowrap="nowrap"><b>Six Month<br />Period Ended<br />March 31, 2017</b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="width: 879px;">Stock price</td> <td style="width: 14px;"> </td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 186px;">1.57</td> <td style="text-align: left; width: 13px;"> </td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 186px;">2.07</td> <td style="text-align: left; width: 13px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Exercise price</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">1.57</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">2.25</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Expected term, years</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4.87</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5.24</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Dividend yield</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"><font style="font-size: 10pt;">-</font></td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;"> </font></td> <td style="text-align: right;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</font></td> <td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">%</font></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td>Volatility</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">94</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">112</td> <td style="text-align: left;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Risk free rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.6</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.0</td> <td style="text-align: left;">%</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company recorded a benefit of $285,045 and expense of $537,904 as stock compensation for the three month periods ended March 31, 2018 and 2017, respectively. The Company recorded a benefit of $53,932 and expense of $1,995,924 as stock compensation expense for the six month periods ended March 31, 2018 and 2017, respectively. The benefits during the three and six month periods ended March 31, 2018 are the result of the reversal of the expense of $415,786 previously recorded for certain performance based stock options that were cancelled and therefore the performance conditions were no longer probable and the options did not vest. As of March 31, 2018, unrecorded compensation cost related to non-vested awards was $1,024,483, which is expected to be recognized over a weighted average period of approximately 1.25 years. The weighted average grant date fair value per share for options granted during the six month period ended March 31, 2018 was $1.13.</p>

<div style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>NOTE G — COMMITMENTS AND CONTINGENCIES</b></div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Operating Leases</u></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company leases office space under an operating lease in Stony Brook, New York for its corporate headquarters. The lease is for a 30,000 square foot building. The term of the lease commenced on June 15, 2013 and expired on May 31, 2016, with the option to extend the lease for two additional three-year periods. The Company has exercised its option to extend the lease for one additional three-year period ending May 31, 2019. The base rent during the additional three-year period is $458,098 per annum. In addition to the office space, the Company also has 1,500 square feet of laboratory space. The term of the lease commenced on November 1, 2015 and expired on October 31, 2017. Effective November 20, 2017, the Company renewed this lease for one additional year, ending October 31, 2018. The Company set up a satellite testing facility in Ahmedabad, India during fiscal 2017. On November 17, 2017, it leased 1,108 square feet for a three-year term beginning November 1, 2017. The base rent is approximately $6,500 per annum.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Total rent expense for the three and six month periods ended March 31, 2018 were $138,076 and $271,293, respectively. Total rent expense for the three and six month period ended March 31, 2017 were $142,768 and $283,165, respectively.</p> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Employment Agreement</u></p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="background-color: white;">The Company has an employment agreement with Dr. James Hayward, its Chief Executive Officer effective July 1, 2016. The initial term was through June 30, 2017, with automatic one-year renewal periods. </font>As of June 30, 2017, the employment contract renewed for an additional year. <font style="background-color: white;">Under the agreement, Dr. Hayward will be eligible for a special cash incentive bonus of up to $800,000, $300,000 of which will be payable if and when annual revenue reaches $8 million and $100,000 of which would be payable for each $2 million of annual revenue in excess of $8 million.  Dr Hayward's annual salary under the agreement was $400,000.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Effective May 7, 2016, the Chief Executive Officer's annual salary was voluntarily reduced by $100,000. Effective May 20, 2017, the Chief Executive Officer’s annual salary was voluntarily reduced by an additional $50,000. Accordingly, his current annual base salary as of March 31, 2018 is $250,000. Effective March 15, 2018, the Compensation Committee of the Company’s Board of Directors, approved that the $150,000 reduction in the Chief Executive Officer’s annual salary will be accrued and repaid to the Chief Executive Officer when the Company reaches $3,000,000 in revenues for two consecutive quarters or $12,000,000 in revenues for a fiscal year.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Litigation</u></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time.</div>

<div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>NOTE H– GEOGRAPHIC AREA INFORMATION</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 9pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Net revenues by geographic location of customers are as follows: </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b> </b></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 62%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="8" nowrap="nowrap">Three Month Period Ended March 31,</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2018</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; width: 541px;">United States</td> <td style="width: 9px;"> </td> <td style="text-align: left; width: 9px;">$</td> <td style="text-align: right; width: 127px;">231,392</td> <td style="text-align: left; width: 8px;"> </td> <td style="width: 8px;"> </td> <td style="text-align: left; width: 8px;">$</td> <td style="text-align: right; width: 126px;">555,043</td> <td style="text-align: left; width: 8px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Europe</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">378,834</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">338,005</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Asia and other</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">433,720</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">12,325</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Total</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">1,043,946</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">905,373</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b> </b> </p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 62%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="8" nowrap="nowrap">Six Month Period Ended March 31,</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2018</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; width: 541px;">United States</td> <td style="width: 9px;"> </td> <td style="text-align: left; width: 9px;">$</td> <td style="text-align: right; width: 127px;">524,122</td> <td style="text-align: left; width: 8px;"> </td> <td style="width: 8px;"> </td> <td style="text-align: left; width: 8px;">$</td> <td style="text-align: right; width: 126px;">1,143,942</td> <td style="text-align: left; width: 8px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Europe</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">570,662</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">632,339</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Asia and other</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">596,839</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">32,100</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Total</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">1,691,623</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">1,808,381</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table> </div>

<div> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Income Taxes</u></div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company estimates the degree to which tax assets and credit carry forwards will result in a benefit based on expected profitability by tax jurisdiction.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In its interim financial statements, the Company follows the guidance in ASC 270, “Interim Reporting” and ASC 740 “Income Taxes”, whereby the Company utilizes the expected annual effective tax rate in determining its income tax provisions for the interim periods. That rate differs from U.S. statutory rates primarily as a result of valuation allowance related to the Company’s net operating loss carryforward as a result of the historical losses of the Company.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code that will affect the Company’s fiscal year ending September 30, 2018, including, but not limited to, reducing the U.S. federal corporate tax rate.  The Tax Act reduces the federal corporate tax rate to 21 percent in the fiscal year ending September 30, 2018.  Section 15 of the Internal Revenue Code stipulates that our fiscal year ending September 30, 2018, will have a blended corporate tax rate of approximately 25 percent, which is based on the applicable tax rates before and after the Tax Act and the number of days in the year.  The reduction of the corporate tax rate will cause the Company to reduce its deferred tax asset to the lower federal base rate of 21% and adjust the allowance against the deferred tax asset by the same amount. The Company has not yet determined the impact the rate reduction will have on its gross deferred tax asset and liabilities and offsetting valuation allowance. The Company has a full allowance against the deferred tax asset and as a result there was no impact to income tax expense for the three and six month periods ended March 31, 2018.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The changes included in the Tax Act are broad and complex. The final transition impacts of the Tax Act may differ from the above estimate, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the Company has utilized to calculate the transition impact. The Securities Exchange Commission has issued rules that would allow for a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts. We currently anticipate finalizing and recording any resulting adjustments by the end of our current fiscal year ending September 30, 2018.</div> </div>

<div> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Net Loss Per Share</u></div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">For the three and six month periods ended March 31, 2018 and 2017, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Securities that could potentially dilute basic net income per share in the future were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive for the three and six month periods ended March 31, 2018 and 2017 are as follows: </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2018</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-left: 0in; width: 933px;">Warrants</td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;"> </td> <td style="text-align: right; width: 96px;">12,271,686</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;"> </td> <td style="text-align: right; width: 95px;">9,548,969</td> <td style="text-align: left; width: 11px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Stock options</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">5,320,308</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">5,199,477</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-bottom: 1pt; text-indent: -2in; padding-left: 2in;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">17,591,994</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">14,748,446</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table> </div>

<table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2018</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-left: 0in; width: 933px;">Warrants</td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;"> </td> <td style="text-align: right; width: 96px;">12,271,686</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;"> </td> <td style="text-align: right; width: 95px;">9,548,969</td> <td style="text-align: left; width: 11px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Stock options</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">5,320,308</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">5,199,477</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-bottom: 1pt; text-indent: -2in; padding-left: 2in;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">17,591,994</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">14,748,446</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table>

<table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>March, 2018,<br />2018</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>September 30, <br />2017</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><b> </b></td> <td><b> </b></td> <td style="text-align: center;" colspan="2" nowrap="nowrap"><b>(unaudited)</b></td> <td><b> </b></td> <td><b> </b></td> <td style="text-align: center;" colspan="2" nowrap="nowrap"><b> </b></td> <td><b> </b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0in; width: 933px;">Raw materials</td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 96px;">221,383</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 95px;">193,069</td> <td style="text-align: left; width: 11px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Finished goods</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">72,455</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">133,399</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Total</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">293,838</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">326,468</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table>

<table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>March 31,<br />2018</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>September 30, <br />2017</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 5.4pt;"><b> </b></td> <td><b> </b></td> <td style="text-align: center;" colspan="2"><font style="font-size: 10pt;"><b> (unaudited)</b></font></td> <td style="text-align: left;"><b> </b></td> <td><b> </b></td> <td style="text-align: left;"><b> </b></td> <td style="text-align: right;"><b> </b></td> <td style="text-align: left;"><b> </b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0in; width: 933px;">Accounts payable</td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 96px;">439,212</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 95px;">382,984</td> <td style="text-align: left; width: 11px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0in;">Accrued salaries payable</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">472,372</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">446,012</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Other accrued expenses</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">110,493</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">115,137</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Total</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">1,022,077</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">944,133</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table>

<table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Number of <br />Shares</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="padding-bottom: 1pt;"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Weighted <br />Average <br />Exercise <br />Price Per <br />Share</b></td> <td style="padding-bottom: 1pt;"><b> </b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-left: 0in; width: 933px;">Balance at October 1, 2017</td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;"> </td> <td style="text-align: right; width: 96px;">9,540,455</td> <td style="text-align: left; width: 12px;"> </td> <td style="width: 12px;"> </td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 95px;">3.60</td> <td style="text-align: left; width: 11px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 0in;">Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,735,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.00</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-left: 0in;">Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Cancelled or expired</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(3,769</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">3.32</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Balance at March 31, 2018</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">12,271,686</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">3.24</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table>

<table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 85%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Number of <br />Shares</b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Weighted <br />Average <br />Exercise <br />Price Per <br />Share</b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Aggregate <br />Intrinsic <br />Value</b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap"><b>Weighted Average Contractual Life<br />(Years)</b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="width: 680px;">Outstanding at October 1, 2017</td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 13px;"> </td> <td style="text-align: right; width: 104px;">5,333,227</td> <td style="text-align: left; width: 13px;"> </td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 103px;">3.71</td> <td style="text-align: left; width: 13px;"> </td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 13px;"> </td> <td style="text-align: right; width: 104px;"> </td> <td style="text-align: left; width: 13px;"> </td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 18px;"> </td> <td style="text-align: right; width: 184px;"> </td> <td style="text-align: left; width: 13px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">556,147</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.57</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td>Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Cancelled or expired</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(569,066</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(3.23</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td>Outstanding at March 31, 2018</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5,320,308</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">3.53</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center; vertical-align: bottom;">4.16</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Vested at March 31, 2018</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">4,527,351</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;">$</td> <td style="text-align: right; padding-bottom: 1pt;">3.82</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom;">3.84</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Non-vested at March 31, 2018</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">792,957</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table>

<table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 76%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="white-space: nowrap;" nowrap="nowrap"><b> </b></td> <td style="padding-bottom: 1pt; white-space: nowrap;" nowrap="nowrap"><b> </b></td> <td style="border-bottom: black 1pt solid; text-align: center; white-space: nowrap;" colspan="2" nowrap="nowrap"><b>Six Month <br />Period Ended <br />March 31, 2018</b></td> <td style="padding-bottom: 1pt; white-space: nowrap;" nowrap="nowrap"><b> </b></td> <td nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; white-space: nowrap;" colspan="2" nowrap="nowrap"><b>Six Month<br />Period Ended<br />March 31, 2017</b></td> <td style="padding-bottom: 1pt;" nowrap="nowrap"><b> </b></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="width: 879px;">Stock price</td> <td style="width: 14px;"> </td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 186px;">1.57</td> <td style="text-align: left; width: 13px;"> </td> <td style="width: 13px;"> </td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 186px;">2.07</td> <td style="text-align: left; width: 13px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Exercise price</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">1.57</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">2.25</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left;">Expected term, years</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4.87</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5.24</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Dividend yield</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"><font style="font-size: 10pt;">-</font></td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;"> </font></td> <td style="text-align: right;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</font></td> <td style="text-align: left;"><font style="font-family: 'times new roman', times, serif;">%</font></td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td>Volatility</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">94</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">112</td> <td style="text-align: left;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Risk free rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.6</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.0</td> <td style="text-align: left;">%</td> </tr> </table> <div> </div>

<table style="widows: 2; text-transform: none; text-indent: 0px; width: 62%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="8" nowrap="nowrap">Three Month Period Ended March 31,</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2018</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; width: 541px;">United States</td> <td style="width: 9px;"> </td> <td style="text-align: left; width: 9px;">$</td> <td style="text-align: right; width: 127px;">231,392</td> <td style="text-align: left; width: 8px;"> </td> <td style="width: 8px;"> </td> <td style="text-align: left; width: 8px;">$</td> <td style="text-align: right; width: 126px;">555,043</td> <td style="text-align: left; width: 8px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Europe</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">378,834</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">338,005</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Asia and other</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">433,720</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">12,325</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Total</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">1,043,946</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">905,373</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b> </b> </p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 62%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="8" nowrap="nowrap">Six Month Period Ended March 31,</td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2018</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; width: 541px;">United States</td> <td style="width: 9px;"> </td> <td style="text-align: left; width: 9px;">$</td> <td style="text-align: right; width: 127px;">524,122</td> <td style="text-align: left; width: 8px;"> </td> <td style="width: 8px;"> </td> <td style="text-align: left; width: 8px;">$</td> <td style="text-align: right; width: 126px;">1,143,942</td> <td style="text-align: left; width: 8px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Europe</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">570,662</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">632,339</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #cceeff; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Asia and other</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">596,839</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">32,100</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Total</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">1,691,623</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">1,808,381</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> </table>

14748446

9548969

5199477

17591994

12271686

5320308

187010

374020

0.21

0.31

0.93

0.19

0.41

0.12

0.10

0.15

0.17

0.22

0.18

0.11

0.28

0.66

2 2 2 5 3 2 3877941

2735000

1.75

2735000

4786250

4200000

193069

221383

133399

72455

382984

439212

446012

472372

115137

110493

4786250

2.00

4200000 0.44

5.00

3.53

3.71

P20D

9540455

12271686

2735000 0 3769 3.60 3.24 2.00 0.00 -3.32

5320308

5333227

556147

569066

4527351

792957

1.57

0.00

3.23

3.82

P4Y1M28D

P3Y10M2D

2.07

1.57

2.25

1.57

P5Y2M27D

P4Y10M13D

0.00

1.12

0.94

0.02

0.026

8333333

833334

275752

5842876

1024483

P1Y3M0D

1.13

30000

P3Y

458098 1500 1108 P3Y

142768

283165

138076

271293

P1Y P1Y 800000 300000 8000000 100000 2000000

400000

250000

100000 50000 150000 6500 415786 415786 3000000 12000000 <div> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><u>Business and Basis of Presentation</u></div> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company is principally devoted to developing and marketing plant-based or other DNA technology solutions in the United States, Europe and Asia. To date, the Company has produced limited recurring revenues from its products and services and has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment and development of a biotechnology company.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc., Applied DNA Sciences Europe Limited, and Applied DNA Sciences India Private Limited. Applied DNA Sciences India Private Limited was incorporated in India on June 22, 2017. Significant inter-company transactions and balances have been eliminated in consolidation.</div> </div>

0.25

0000744452us-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2018-01-012018-03-31 0000744452us-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2017-10-012018-03-31 0000744452apdn:FirstCustomerMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2017-01-012017-03-31 0000744452apdn:FirstCustomerMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2016-10-012017-03-31

0.19

0000744452apdn:NonEmployeeBoardOfDirectorMemberus-gaap:EmployeeStockOptionMember2017-10-012018-03-31

556147

0000744452us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberapdn:TwoCustomersMember2016-10-012017-09-30

EX-101.SCH 7 apdn-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - SUMMARY OF ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - INVENTORIES link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - CAPITAL STOCK link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - GEOGRAPHIC AREA INFORMATION link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - INVENTORIES (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - GEOGRAPHIC AREA INFORMATION (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - INVENTORIES (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - CAPITAL STOCK (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees and consultants (Details 1) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - STOCK OPTIONS AND WARRANTS - Fair value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details 2) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - STOCK OPTIONS AND WARRANTS (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - GEOGRAPHIC AREA INFORMATION (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 apdn-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 apdn-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 apdn-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Class Of Stock [Axis] Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series Preferred Stock [Member] Series A Preferred stock Series B Preferred Stock [Member] Series B Preferred stock Statement [Line Items] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, At Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Accounts Receivable, Net, Current Accounts receivable, net of allowance of $10,000 at March 31, 2018 and September 30, 2017 Accounts receivable Inventory, Net Inventories Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Total current assets Property, Plant and Equipment, Net Property and equipment, net Property plant and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Assets, Noncurrent [Abstract] Other assets: Deposits Assets, Noncurrent Deposits Goodwill Goodwill Finite-Lived Intangible Assets, Net Amortization on intangible assets Intangible assets, net Net Assets Total Assets Total Assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Total Deferred Revenue, Current Deferred revenue Deferred revenue Liabilities Total current liabilities Commitments and Contingencies Commitments and contingencies Stockholders Equity Attributable To Parent [Abstract] Stockholders' Equity Preferred Stock, Value, Issued Preferred stock, value Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2014 and September 30, 2013 Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Common Stock, Value, Issued Common stock, par value $0.001 per share; 500,000,000 shares authorized; 30,112,057 and 27,377,057 shares issued and outstanding as of March 31, 2018 and September 30, 2017, respectively Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Additional Paid in Capital, Common Stock Additional paid in capital Retained Earnings (Accumulated Deficit) Accumulated losses Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Stockholders' Equity Attributable To Parent Balance Total stockholders' equity Balance Balance Liabilities and Equity Total Liabilities and Stockholders' Equity (Deficit) Total Liabilities and Stockholders' Equity Allowance for Doubtful Accounts Receivable, Current Allowance on accounts receivable (in dollars) Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common stock, shares outstanding Balance (in shares) Balance (in shares) Income Statement [Abstract] Income Statement [Abstract] Revenue, Net [Abstract] Revenues: Sales Revenue, Goods, Net Product revenues Sales Revenue, Services, Net Service revenues Revenue, Net Net sales Total revenues Total revenues Cost of Revenue Cost of revenues Operating Expenses [Abstract] Operating expenses: Selling, General and Administrative Expense Selling, general and administrative Selling, general and administrative Research and Development Expense Research and development Research and development expenses Research and development Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Depreciation and amortization Operating Expenses Total operating expenses Total operating expenses Operating Income (Loss) NET LOSS FROM OPERATIONS LOSS FROM OPERATIONS Nonoperating Income (Expense) [Abstract] Other income (expense): Interest Income (Expense), Nonoperating, Net Interest income, net Interest expense, net (Note C) Interest income (expense), net Other Nonoperating Income (Expense) Other expense Other (expense) income, net Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before provision for income taxes Loss before provision for income taxes Net loss before provision for income taxes Income Tax Expense (Benefit) Provision for income taxes Income taxes (benefit) Net Income (Loss) Attributable To Parent Net loss NET LOSS NET LOSS Earnings Per Share, Basic and Diluted Net Loss per share - basic and diluted Net loss per share-basic and diluted (in dollars per share) Net (loss) per share-basic and fully diluted Net loss per share-basic and diluted Weighted Average Number Of Shares Outstanding, Basic and Diluted Weighted average shares outstanding- Basic and diluted (in shares) Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Depreciation and amortization Stock based compensation expense Stock compensation expense Stock-based compensation Equity based compensation Fair value of vested warrants issued for services Provision for Doubtful Accounts Provision for bad debts Increase (Decrease) In Operating Capital [Abstract] Change in operating assets and liabilities: Increase (Decrease) In Accounts Receivable (Increase) decrease in accounts receivable Accounts receivable Increase (Decrease) in Inventories Inventories Inventories Increase (Decrease) In Prepaid Expense and Other Assets Decrease in prepaid expenses and deposits Decrease in prepaid expenses and deposits Prepaid expenses and other current assets and deposits Increase (Decrease) In Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities (Decrease) increase in accounts payable and accrued liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Used In Operating Activities Negative operating cash flow Net cash used in operating activities Net cash used in operating activities Net Cash Provided By (Used In) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments To Acquire Property, Plant, and Equipment Purchase of property and equipment Purchase of property and equipment Net Cash Provided By (Used In) Investing Activities, Continuing Operations Cash flows from investing activities Net cash used in investing activities Net Cash Provided By (Used In) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Net Proceeds From Sale Of Common Stock And Warrants Net proceeds from sale of common stock and warrants The cash inflow from common stock and warrants after deducting after deducting underwriting discounts, offering expenses and the repurchase the remaining Series B Warrants from Crede to the entity. Net proceeds from sale of common stock and warrants Net Cash Provided By (Used In) Financing Activities, Continuing Operations Net cash provided by financing activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in cash and cash equivalents Net increase (decrease) in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental Disclosures of Cash Flow Information: Interest Paid Cash paid during period for interest Income Taxes Paid Cash paid during period for income taxes Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing and financing activities: Property Plant And Equipment Acquired And Included In Accounts Payable Property and equipment acquired, and included in accounts payable It represents property, plant and equipment acquired includes in accounts payable Accounting Policies [Abstract] Accounting Policies [Abstract] Organization, Consolidation, Basis Of Presentation, Business Description and Accounting Policies [Text Block] Business and Basis of Presentation SUMMARY OF ACCOUNTING POLICIES Liquidity And Management Plan [Abstract] Liquidity And Management Plan [Text Block] LIQUIDITY AND MANAGEMENT'S PLAN The entire disclosure about liquidity and management plan. Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Inventories Payables and Accruals [Abstract] Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts payable and accrued liabilities Stockholders' Equity Note [Abstract] Capital Stock [Abstract] Shareholders' Equity and Share-Based Payments [Text Block] CAPITAL STOCK Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] STOCK OPTIONS AND WARRANTS Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Segment Reporting [Abstract] Segment Reporting Disclosure [Text Block] GEOGRAPHIC AREA INFORMATION Basis of Accounting, Policy [Policy Text Block] Business and Basis of Presentation General Business And Basis Of Presentation [Policy Text Block] Business and Basis of Presentation Disclosure of accounting policy for business and basis of presentation. Inventory, Policy [Policy Text Block] Inventories Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Use of Estimates, Policy [Policy Text Block] Use of Estimates Income Tax, Policy [Policy Text Block] Income Taxes Income Taxes Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-based compensation Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of anti-dilutive securities not included computation of net loss per share Schedule of Inventory, Current [Table Text Block] Schedule of inventories Schedule Of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable and accrued liabilities Schedule Of Disclosure Transactions Of Warrants [Table Text Block] Schedule of transactions involving warrants Tabular disclosure of components of transactions of warrants. Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of transactions involving stock options issued to employees and consultants Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Schedule of fair value of options granted Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Schedule of net sales by geographic location of customers Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Warrant [Member] Warrants Stock Options Stock Options Employee options Stock options Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from diluted net loss per share Revenue for government contract awards Revenue for government contract awards Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent US corporate income tax rate Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Customer Concentration Risk Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales [Member] Total Revenue Accounts Receivable [Member] Accounts Receivable Major Customers [Axis] Concentration Risk Type [Axis] Name Of Major Customer [Domain] Concentration Risk Type [Domain] First Customer Member First customer It represents number of major customers in concentration risk. Second Customer Member Second customer It represents number of major customers in concentration risk. Third Customer [Member] Third customer It represents number of major customers in concentration risk. Two Customers [Member] Two customers It represents number of major customers in Fourth Customer [Member] Fourth customer It represents number of major customers in concentration risk. Fifth Customer [Member] Fifth customer It represents number of major customers in concentration risk. Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration Risk, Percentage Percentage of total revenue and accounts receivable Concentration Risk Number Of Customers Number of customers It represents number of major customers in concentration risk. Liquidity And Management Plan [Table] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Securities Purchase Agreement [Member] Securities Purchase Agreement Represents securities purchase agreement. Sale of Stock [Axis] Sale of Stock [Domain] Private Placement [Member] Private placement Liquidity And Management Plan [Line Items] Working Capital Surplus Deficit Working capital It represents working capital surplus deficit. Stock Issued During Period, Shares, New Issues Underwritten public offering of common stock and warrants closed Number of shares issued Common stock issued in private placement, net of offering costs (in shares) Shares Issued, Price Per Share Share price (in dollars per share) Share issued (Price per share) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of common stock called by warrants Number of common stock called by warrants Number of common stock called by warrants Aggregate shares of common stock issued Proceeds from Issuance of Private Placement Aggregate gross proceeds from Registered Direct Offering Proceeds from issuance of common stock under private placement Proceeds from Issuance Initial Public Offering Net proceeds from sale of Registered Direct Offering Inventory, Raw Materials, Gross Raw materials Inventory, Finished Goods, Gross Finished goods Accounts Payable, Current Accounts payable Accrued Salaries, Current Accrued salaries payable Other Accrued Liabilities, Current Other accrued expenses Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Gross Proceeds From Common Stock And Warrants Upon Closure Of Direct Public Offering And Private Placement Aggregate gross proceeds Gross proceeds from common stock and warrants upon closure of private placement Represents gross proceeds from common stock and warrants upon closure of direct public offering and private placement. Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrants Exercise price of warrants (in dollars per share) Net Proceeds After Deducting Placement Agent Fees And Offering Expenses Net proceeds after deducting placement agent fees and offering expenses Represents amount of net proceeds after deducting the placement agent fees and offering expenses. Minimum Exercise Price Minimum exercise price Represents minimum exercise price. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average price of common stock exceeded (in dollars per share) Weighted Average Exercise Price of Options Outstanding Options Outstanding, Weighted Average Exercise Price Outstanding at October 1, 2017 Outstanding at March 31, 2018 Number Of Trading Days For Call Cancellation Number of trading days for call cancellation Number of trading days for call cancellation in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class Of Warrant Or Right, Number Of Shares [Roll Forward] Number of Shares A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Number of warrants granted Number Outstanding Balance at October 1, 2015 Balance at October 1, 2017 Balance at March 31, 2018 Class Of Warrant Or Right Granted Number of shares of common stock granted Granted Represents number of warrants granted to participants. Class Of Warrant Or Right Exercised Exercised Cashless exercise of warrant Represents the number of warrants exercised by participants. Exercised EX-101.PRE 11 apdn-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	Apr. 30, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	APPLIED DNA SCIENCES INC
Entity Central Index Key	0000744452
Trading Symbol	apdn
Current Fiscal Year End Date	--09-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		30,112,057
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2018	Sep. 30, 2017
Current assets:
Cash and cash equivalents	$ 3,709,402	$ 2,959,781
Accounts receivable, net of allowance of $10,000 at March 31, 2018 and September 30, 2017	1,525,715	2,587,969
Inventories	293,838	326,468
Prepaid expenses and other current assets	575,414	366,954
Total current assets	6,104,369	6,241,172
Property and equipment, net	550,907	523,688
Other assets:
Deposits	62,437	61,626
Goodwill	285,386	285,386
Intangible assets, net	930,444	1,042,076
Total Assets	7,933,543	8,153,948
Current liabilities:
Accounts payable and accrued liabilities	1,022,077	944,133
Deferred revenue	1,204,351	351,735
Total current liabilities	2,226,428	1,295,868
Commitments and contingencies
Stockholders' Equity
Preferred stock, value
Common stock, par value $0.001 per share; 500,000,000 shares authorized; 30,112,057 and 27,377,057 shares issued and outstanding as of March 31, 2018 and September 30, 2017, respectively	30,112	27,377
Additional paid in capital	247,680,080	243,503,858
Accumulated deficit	(242,003,077)	(236,673,155)
Total stockholders' equity	5,707,115	6,858,080
Total Liabilities and Stockholders' Equity	7,933,543	8,153,948
Series A Preferred stock
Stockholders' Equity
Preferred stock, value
Series B Preferred stock
Stockholders' Equity
Preferred stock, value

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Mar. 31, 2018	Sep. 30, 2017
Allowance on accounts receivable (in dollars)	$ 10,000	$ 10,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	30,112,057	27,377,057
Common stock, shares outstanding	30,112,057	27,377,057
Series A Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Product revenues	$ 486,341	$ 689,188	$ 836,474	$ 1,393,605
Service revenues	557,605	216,185	855,149	414,776
Total revenues	1,043,946	905,373	1,691,623	1,808,381
Cost of revenues	372,153	297,372	703,593	572,204
Operating expenses:
Selling, general and administrative	1,996,604	3,230,371	4,589,759	7,131,288
Research and development	669,813	635,893	1,409,880	1,154,521
Depreciation and amortization	145,280	163,368	302,928	325,345
Total operating expenses	2,811,697	4,029,632	6,302,567	8,611,154
LOSS FROM OPERATIONS	(2,139,904)	(3,421,631)	(5,314,537)	(7,374,977)
Other income (expense):
Interest income, net		1,204		2,535
Other expense	(6,305)	(8,429)	(15,385)	(17,798)
Loss before provision for income taxes	(2,146,209)	(3,428,856)	(5,329,922)	(7,390,240)
Provision for income taxes	0	0	0	0
NET LOSS	$ (2,146,209)	$ (3,428,856)	$ (5,329,922)	$ (7,390,240)
Net loss per share-basic and diluted (in dollars per share)	$ (0.07)	$ (0.13)	$ (0.18)	$ (0.29)
Weighted average shares outstanding- Basic and diluted (in shares)	30,112,057	26,351,483	28,879,804	25,886,892

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (5,329,922)	$ (7,390,240)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	302,928	325,345
Stock-based compensation	(53,932)	1,995,924
Provision for bad debts	17,117	21,247
Change in operating assets and liabilities:
Accounts receivable	1,045,136	1,651,510
Inventories	32,630	(55,823)
Prepaid expenses and other current assets and deposits	(209,269)	16,658
Accounts payable and accrued liabilities	62,945	(414,822)
Deferred revenue	852,616	(848,814)
Net cash used in operating activities	(3,279,751)	(4,699,015)
Cash flows from investing activities:
Purchase of property and equipment	(203,516)	(93,694)
Net cash used in investing activities	(203,516)	(93,694)
Cash flows from financing activities:
Net proceeds from sale of common stock and warrants	4,232,888	4,333,847
Net cash provided by financing activities	4,232,888	4,333,847
Net increase (decrease) in cash and cash equivalents	749,621	(458,862)
Cash and cash equivalents at beginning of period	2,959,781	4,479,274
Cash and cash equivalents at end of period	3,709,402	4,020,412
Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest	0	0
Cash paid during period for income taxes	0	0
Non-cash investing and financing activities:
Property and equipment acquired, and included in accounts payable	$ 15,000	$ 60,468

XML 17 R6.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES

6 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

SUMMARY OF ACCOUNTING POLICIES

NOTE A — SUMMARY OF ACCOUNTING POLICIES

General

Business and Basis of Presentation

Inventories

Inventories, which consist primarily of raw materials, and finished goods, is stated at the lower of cost or net realizable value, with cost determined by using the first-in, first-out (FIFO) method.

Revenue Recognition

Use of Estimates

Income Taxes

Net Loss Per Share

	2018		2017

Warrants		12,271,686		9,548,969
Stock options		5,320,308		5,199,477
		17,591,994		14,748,446

Stock-Based Compensation

Concentrations

Two customers accounted for 66% and 93% of the Company’s accounts receivable at March 31, 2018 and September 30, 2017, respectively.

Recent Accounting Pronouncements

XML 18 R7.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND MANAGEMENT'S PLAN	6 Months Ended
LIQUIDITY AND MANAGEMENT'S PLAN	Mar. 31, 2018
Liquidity And Management Plan [Abstract]
LIQUIDITY AND MANAGEMENT'S PLAN	NOTE B — LIQUIDITY AND MANAGEMENT’S PLAN The Company has recurring net losses, which have resulted in an accumulated deficit of $242,003,077 as of March 31, 2018. The Company incurred a net loss of $5,329,922 and generated negative operating cash flow of $3,279,751 for the six month period ended March 31, 2018. The Company also had working capital of $3,877,941 and cash and cash equivalents of $3,709,402 as of March 31, 2018. The Company’s current capital resources include cash and cash equivalents, accounts receivable, and inventories. Historically, the Company has financed its operations principally from the sale of equity securities. As discussed in Note E, on December 20, 2017, the Company entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 2,735,000 shares of the Company’s common stock and warrants to purchase an aggregate of 2,735,000 shares of common stock in a registered direct offering with an aggregate gross proceeds of $4,786,250, at a combined purchase price of $1.75 per share for total net proceeds of approximately $4,200,000, after placement agent fees and other estimated offering costs. The offering closed on December 22, 2017. Management has evaluated relevant conditions and events with respect to liquidity requirements for the twelve month period after the Company’s March 31, 2018 financial statements are filed with the SEC. If the Company does not meet its forecasted revenues for the next twelve months, it would not have sufficient cash and cash equivalents to cover the Company’s operating expenses. Due to this condition, management of the Company has established a plan, which has been approved by its Board of Directors, that includes potential financing options and/or cost saving measures that will be implemented if revenue targets are not met within a specified time period. Management believes that it is probable that such plan, if implemented, will result in the liquidity deemed necessary for the Company to mitigate the relevant conditions that raised substantial doubt about the Company’s ability to continue as a going concern one year after the date the financial statements are issued. Management believes that the Company’s cash balances on hand, collection of its accounts receivable, reduced cash burn from cost saving measures and proceeds from a potential financing will be sufficient to fund the Company’s net cash requirements for the next twelve months from the date of filing this quarterly report.

XML 19 R8.htm IDEA: XBRL DOCUMENT

INVENTORIES

6 Months Ended

Mar. 31, 2018

Inventory Disclosure [Abstract]

Inventories

NOTE C — INVENTORIES

Inventories consist of the following:

	March, 2018, 2018		September 30, 2017
	(unaudited)
Raw materials	$	221,383	$	193,069
Finished goods		72,455		133,399
Total	$	293,838	$	326,468

XML 20 R9.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

6 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

Accounts payable and accrued liabilities

NOTE D — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities are as follows:

	March 31, 2018		September 30, 2017
	(unaudited)
Accounts payable	$	439,212	$	382,984
Accrued salaries payable		472,372		446,012
Other accrued expenses		110,493		115,137
Total	$	1,022,077	$	944,133

XML 21 R10.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK	6 Months Ended
CAPITAL STOCK	Mar. 31, 2018
Stockholders' Equity Note [Abstract]
CAPITAL STOCK	NOTE E — CAPITAL STOCK On December 20, 2017, the Company entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,735,000 shares of its common stock and warrants to purchase an aggregate of 2,735,000 shares of common stock in a registered direct offering with aggregate gross proceeds of $4,786,250, at a combined purchase price of $1.75 per share and warrant. The warrants will be immediately exercisable at a price of $2.00 per share of common stock and will expire five years from the date of issuance. After deducting placement agent fees and other estimated expenses related to the registered direct offering, the aggregate net proceeds were approximately $4,200,000. The warrants include an adjustment provision that, subject to certain exceptions, reduces their exercise price if the Company issues common stock or common stock equivalents at a price lower than the then-current exercise price of the warrants, subject to a minimum exercise price of $0.44. The exercise price and number of the shares of the Company’s common stock issuable upon the exercise of the warrants will be subject to adjustment as set forth therein (including for stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction). The warrants are subject to a call provision whereby the Company may, subject to certain provisions, including that the weighted average price of the Company’s common stock has exceeded $5.00 for twenty consecutive trading days, call for cancellation of all or any portion of the warrants not yet exercised. In addition, if and only if there is no effective registration statement registering, or no current prospectus available for, the resale of the warrants, the Purchasers may exercise the warrants by means of a “cashless exercise.” The offering closed on December 22, 2017.

XML 22 R11.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS

6 Months Ended

Mar. 31, 2018

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

STOCK OPTIONS AND WARRANTS

NOTE F — STOCK OPTIONS AND WARRANTS

Warrants

The following table summarizes the changes in warrants outstanding and the related prices for the shares of common stock issued to non-employees of the Company.

Transactions involving warrants are summarized as follows:

	Number of Shares			Weighted Average Exercise Price Per Share
Balance at October 1, 2017		9,540,455		$	3.60
Granted		2,735,000			2.00
Exercised		-			-
Cancelled or expired		(3,769	)		3.32
Balance at March 31, 2018		12,271,686		$	3.24

Stock Options

Transactions involving stock options issued to employees and consultants are summarized as follows:

	Number of Shares			Weighted Average Exercise Price Per Share			Aggregate Intrinsic Value		Weighted Average Contractual Life (Years)
Outstanding at October 1, 2017		5,333,227		$	3.71
Granted		556,147			1.57
Exercised		-			-
Cancelled or expired		(569,066	)		(3.23	)
Outstanding at March 31, 2018		5,320,308		$	3.53					4.16
Vested at March 31, 2018		4,527,351		$	3.82		$	-		3.84
Non-vested at March 31, 2018		792,957					$	-

During the six month periods ended March 31, 2018, the Company issued stock options to purchase an aggregate of 556,147 shares to non-employee Board of Director members.

	Six Month Period Ended March 31, 2018			Six Month Period Ended March 31, 2017
Stock price	$	1.57		$	2.07
Exercise price	$	1.57		$	2.25
Expected term, years		4.87			5.24
Dividend yield		-	%		-	%
Volatility		94	%		112	%
Risk free rate		2.6	%		2.0	%

XML 23 R12.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE G — COMMITMENTS AND CONTINGENCIES

Operating Leases

Employment Agreement

Litigation

XML 24 R13.htm IDEA: XBRL DOCUMENT

GEOGRAPHIC AREA INFORMATION

6 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

GEOGRAPHIC AREA INFORMATION

NOTE H– GEOGRAPHIC AREA INFORMATION

Net revenues by geographic location of customers are as follows:

Three Month Period Ended March 31,
	2018		2017
United States	$	231,392	$	555,043
Europe		378,834		338,005
Asia and other		433,720		12,325
Total	$	1,043,946	$	905,373

Six Month Period Ended March 31,
	2018		2017
United States	$	524,122	$	1,143,942
Europe		570,662		632,339
Asia and other		596,839		32,100
Total	$	1,691,623	$	1,808,381

XML 25 R14.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Policies)

6 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

General

Business and Basis of Presentation

Inventories

Inventories, which consist primarily of raw materials, and finished goods, is stated at the lower of cost or net realizable value, with cost determined by using the first-in, first-out (FIFO) method.

	2018		2017

Warrants		12,271,686		9,548,969
Stock options		5,320,308		5,199,477
		17,591,994		14,748,446

Stock-based compensation

Stock-Based Compensation

Concentrations

Two customers accounted for 66% and 93% of the Company’s accounts receivable at March 31, 2018 and September 30, 2017, respectively.

Recent Accounting Pronouncements

XML 26 R15.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Tables)

6 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Schedule of anti-dilutive securities not included computation of net loss per share

	2018		2017

Warrants		12,271,686		9,548,969
Stock options		5,320,308		5,199,477
		17,591,994		14,748,446

XML 27 R16.htm IDEA: XBRL DOCUMENT

INVENTORIES (Tables)

6 Months Ended

Mar. 31, 2018

Inventory Disclosure [Abstract]

Schedule of inventories

	March, 2018, 2018		September 30, 2017
	(unaudited)
Raw materials	$	221,383	$	193,069
Finished goods		72,455		133,399
Total	$	293,838	$	326,468

XML 28 R17.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

6 Months Ended

Mar. 31, 2018

Payables and Accruals [Abstract]

Schedule of accounts payable and accrued liabilities

	March 31, 2018		September 30, 2017
	(unaudited)
Accounts payable	$	439,212	$	382,984
Accrued salaries payable		472,372		446,012
Other accrued expenses		110,493		115,137
Total	$	1,022,077	$	944,133

XML 29 R18.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Tables)

6 Months Ended

Mar. 31, 2018

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Schedule of transactions involving warrants

	Number of Shares			Weighted Average Exercise Price Per Share
Balance at October 1, 2017		9,540,455		$	3.60
Granted		2,735,000			2.00
Exercised		-			-
Cancelled or expired		(3,769	)		3.32
Balance at March 31, 2018		12,271,686		$	3.24

Schedule of transactions involving stock options issued to employees and consultants

	Number of Shares			Weighted Average Exercise Price Per Share			Aggregate Intrinsic Value		Weighted Average Contractual Life (Years)
Outstanding at October 1, 2017		5,333,227		$	3.71
Granted		556,147			1.57
Exercised		-			-
Cancelled or expired		(569,066	)		(3.23	)
Outstanding at March 31, 2018		5,320,308		$	3.53					4.16
Vested at March 31, 2018		4,527,351		$	3.82		$	-		3.84
Non-vested at March 31, 2018		792,957					$	-

Schedule of fair value of options granted

	Six Month Period Ended March 31, 2018			Six Month Period Ended March 31, 2017
Stock price	$	1.57		$	2.07
Exercise price	$	1.57		$	2.25
Expected term, years		4.87			5.24
Dividend yield		-	%		-	%
Volatility		94	%		112	%
Risk free rate		2.6	%		2.0	%

XML 30 R19.htm IDEA: XBRL DOCUMENT

GEOGRAPHIC AREA INFORMATION (Tables)

6 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Schedule of net sales by geographic location of customers

Three Month Period Ended March 31,
	2018		2017
United States	$	231,392	$	555,043
Europe		378,834		338,005
Asia and other		433,720		12,325
Total	$	1,043,946	$	905,373

Six Month Period Ended March 31,
	2018		2017
United States	$	524,122	$	1,143,942
Europe		570,662		632,339
Asia and other		596,839		32,100
Total	$	1,691,623	$	1,808,381

XML 31 R20.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) - shares	6 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net loss per share	17,591,994	14,748,446
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net loss per share	12,271,686	9,548,969
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from diluted net loss per share	5,320,308	5,199,477

XML 32 R21.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2018	Mar. 31, 2018	Sep. 30, 2017
Accounting Policies [Abstract]
Deferred revenue	$ 1,204,351	$ 1,204,351	$ 351,735
Revenue for government contract awards	$ 187,010	$ 374,020
US corporate income tax rate	21.00%
Blended corporate tax rate	25.00%

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) - Customer Concentration Risk - Customer	3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017
Total Revenue
Concentration Risk [Line Items]
Number of customers	5	2	3	2
Total Revenue \| First customer
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	10.00%	19.00%	11.00%	19.00%
Total Revenue \| Second customer
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	12.00%	31.00%	18.00%	41.00%
Total Revenue \| Third customer
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	15.00%		28.00%
Total Revenue \| Fourth customer
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	17.00%
Total Revenue \| Fifth customer
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable	22.00%
Accounts Receivable \| Two customers
Concentration Risk [Line Items]
Percentage of total revenue and accounts receivable			66.00%		93.00%
Number of customers			2		2

XML 34 R23.htm IDEA: XBRL DOCUMENT

LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Dec. 20, 2017	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2016
Liquidity And Management Plan [Line Items]
Accumulated deficit		$ (242,003,077)		$ (242,003,077)		$ (236,673,155)
Net loss		(2,146,209)	$ (3,428,856)	(5,329,922)	$ (7,390,240)
Negative operating cash flow				(3,279,751)	(4,699,015)
Working capital		3,877,941		3,877,941
Cash and cash equivalents		$ 3,709,402	$ 4,020,412	$ 3,709,402	$ 4,020,412	$ 2,959,781	$ 4,479,274
Securities Purchase Agreement \| Private placement
Liquidity And Management Plan [Line Items]
Common stock issued in private placement, net of offering costs (in shares)	2,735,000
Share price (in dollars per share)	$ 1.75
Number of common stock called by warrants	2,735,000
Aggregate gross proceeds from Registered Direct Offering	$ 4,786,250
Net proceeds from sale of Registered Direct Offering	$ 4,200,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

INVENTORIES (Details) - USD ($)	Mar. 31, 2018	Sep. 30, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 221,383	$ 193,069
Finished goods	72,455	133,399
Total	$ 293,838	$ 326,468

XML 36 R25.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) - USD ($)	Mar. 31, 2018	Sep. 30, 2017
Payables and Accruals [Abstract]
Accounts payable	$ 439,212	$ 382,984
Accrued salaries payable	472,372	446,012
Other accrued expenses	110,493	115,137
Total	$ 1,022,077	$ 944,133

XML 37 R26.htm IDEA: XBRL DOCUMENT

CAPITAL STOCK (Detail Textuals) - Private placement - Securities Purchase Agreement	1 Months Ended
	Dec. 20, 2017 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued in private placement, net of offering costs (in shares) \| shares	2,735,000
Number of common stock called by warrants \| shares	2,735,000
Aggregate gross proceeds \| $	$ 4,786,250
Share price (in dollars per share)	$ 1.75
Exercise price of warrants (in dollars per share)	$ 2.00
Net proceeds after deducting placement agent fees and offering expenses \| $	$ 4,200,000
Minimum exercise price	$ 0.44
Weighted average price of common stock exceeded (in dollars per share)	$ 5.00
Number of trading days for call cancellation	20 days

XML 38 R27.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details)	6 Months Ended
	Mar. 31, 2018 $ / shares shares
Number of Shares
Balance at October 1, 2017 \| shares	9,540,455
Granted \| shares	2,735,000
Exercised \| shares	0
Cancelled or expired \| shares	(3,769)
Balance at March 31, 2018 \| shares	12,271,686
Weighted Average Exercise Price Per Share
Balance at October 1, 2017 \| $ / shares	$ 3.60
Granted \| $ / shares	2.00
Exercised \| $ / shares	(0.00)
Cancelled or expired \| $ / shares	3.32
Balance at March 31, 2018 \| $ / shares	$ 3.24

XML 39 R28.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees and consultants (Details 1) - Stock Options - 2005 Incentive Stock Plan (the "Incentive Plan")	6 Months Ended
	Mar. 31, 2018 USD ($) $ / shares shares
Number of Shares
Outstanding at October 1, 2017	5,333,227
Granted	556,147
Exercised	0
Cancelled or expired	(569,066)
Outstanding at March 31, 2018	5,320,308
Vested at March 31, 2018	4,527,351
Non-vested at March 31, 2018	792,957
Weighted Average Exercise Price Per Share
Outstanding at October 1, 2017 \| $ / shares	$ 3.71
Granted \| $ / shares	1.57
Exercised \| $ / shares	0.00
Cancelled or expired \| $ / shares	(3.23)
Outstanding at March 31, 2018 \| $ / shares	3.53
Vested at March 31, 2018 \| $ / shares	$ 3.82
Aggregate Intrinsic Value, Vested at March 31, 2018 \| $	$ 0
Aggregate Intrinsic Value, Non-vested at March 31, 2018 \| $	$ 0
Weighted Average Contractual Life (years), Outstanding at March 31, 2018	4 years 1 month 28 days
Weighted Average Contractual Life (years), Vested at March 31, 2018	3 years 10 months 2 days

XML 40 R29.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS - Fair value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details 2) - $ / shares	6 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Stock price	$ 1.57	$ 2.07
Exercise price	$ 1.57	$ 2.25
Expected term, years	4 years 10 months 13 days	5 years 2 months 27 days
Dividend yield	0.00%	0.00%
Volatility	94.00%	112.00%
Risk free rate	2.60%	2.00%

XML 41 R30.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS AND WARRANTS (Detail Textuals) - USD ($)	3 Months Ended		6 Months Ended
STOCK OPTIONS AND WARRANTS (Detail Textuals) - USD ($)	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation (expense) benefit	$ 285,045	$ (537,904)	$ 53,932	$ (1,995,924)
Unrecorded compensation cost related to non-vested awards	1,024,483		$ 1,024,483
Weighted average period for non-vested awards			1 year 3 months
Weighted average grant date fair value for options granted			$ 1.13
Reversal of expense	$ 415,786		$ 415,786
Stock Options \| Non-employee Board of Director members
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted			556,147
Stock Options \| 2005 Incentive Stock Plan (the "Incentive Plan")
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock that can be issued as stock awards and stock option	8,333,333		8,333,333
Number of common stock shares that can be covered by awards made to any participant per period			833,334
Number of shares issued			275,752
Options to purchase shares under the 2005 Incentive Stock Plan			5,842,876
Number of options granted			556,147

XML 42 R31.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Detail Textuals)		1 Months Ended				3 Months Ended		6 Months Ended
COMMITMENTS AND CONTINGENCIES (Detail Textuals)	Mar. 15, 2018 USD ($)	Dec. 20, 2017	Nov. 17, 2017 USD ($) ft²	Jul. 01, 2016 USD ($)	Jun. 15, 2013 USD ($) ft²	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)	May 20, 2017 USD ($)	May 07, 2016 USD ($)
Commitments And Contingencies [Line Items]
Area of property under operating lease \| ft²					30,000
Extended operating lease for two additional period					3 years
Base rent during initial lease term per annum					$ 458,098
Area of laboratory space \| ft²					1,500
Lease for satellite testing \| ft²			1,108
Base rent per annum			$ 6,500
Term of lease			3 years
Total rent expense						$ 138,076	$ 142,768	$ 271,293	$ 283,165
Agreement renewal period		1 year
Employment Agreement \| Dr. James Hayward - Chief Executive Officer
Commitments And Contingencies [Line Items]
Annual base salary								$ 250,000
Reduction in annual salary	$ 150,000									$ 50,000	$ 100,000
Threshold revenue for two consecutive quarters	3,000,000
Threshold revenue for fiscal year	$ 12,000,000
New Employment Agreement \| Dr. James Hayward - Chief Executive Officer
Commitments And Contingencies [Line Items]
Agreement renewal period				1 year
Special cash incentive bonus				$ 800,000
Special cash incentive bonus on completing threshold annual revenue				300,000
Threshold annual revenue				8,000,000
Special cash incentive bonus on completing threshold annual revenue in excess of first threshold revenue				100,000
Threshold annual revenue in excess of first threshold				2,000,000
Annual base salary				$ 400,000

XML 43 R32.htm IDEA: XBRL DOCUMENT

GEOGRAPHIC AREA INFORMATION (Details) - USD ($)	3 Months Ended		6 Months Ended
GEOGRAPHIC AREA INFORMATION (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Segment Reporting Information [Line Items]
Net sales	$ 1,043,946	$ 905,373	$ 1,691,623	$ 1,808,381
United States
Segment Reporting Information [Line Items]
Net sales	231,392	555,043	524,122	1,143,942
Europe
Segment Reporting Information [Line Items]
Net sales	378,834	338,005	570,662	632,339
Asia and other
Segment Reporting Information [Line Items]
Net sales	$ 433,720	$ 12,325	$ 596,839	$ 32,100

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 45 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 63 176 1 false 24 0 false 6 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.adnas.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.adnas.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.adnas.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.adnas.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.adnas.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - SUMMARY OF ACCOUNTING POLICIES Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIES SUMMARY OF ACCOUNTING POLICIES Notes 6 false false R7.htm 007 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN Sheet http://www.adnas.com/role/LiquidityAndManagementSPlan LIQUIDITY AND MANAGEMENT'S PLAN Notes 7 false false R8.htm 008 - Disclosure - INVENTORIES Sheet http://www.adnas.com/role/Inventories INVENTORIES Notes 8 false false R9.htm 009 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Notes 9 false false R10.htm 010 - Disclosure - CAPITAL STOCK Sheet http://www.adnas.com/role/CAPITALSTOCK CAPITAL STOCK Notes 10 false false R11.htm 011 - Disclosure - STOCK OPTIONS AND WARRANTS Sheet http://www.adnas.com/role/STOCKOPTIONSANDWARRANTS STOCK OPTIONS AND WARRANTS Notes 11 false false R12.htm 012 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.adnas.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 013 - Disclosure - GEOGRAPHIC AREA INFORMATION Sheet http://www.adnas.com/role/GeographicAreaInformation GEOGRAPHIC AREA INFORMATION Notes 13 false false R14.htm 014 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Policies) Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESPolicies SUMMARY OF ACCOUNTING POLICIES (Policies) Policies 14 false false R15.htm 015 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Tables) Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESTables SUMMARY OF ACCOUNTING POLICIES (Tables) Tables http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIES 15 false false R16.htm 016 - Disclosure - INVENTORIES (Tables) Sheet http://www.adnas.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://www.adnas.com/role/Inventories 16 false false R17.htm 017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Tables http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES 17 false false R18.htm 018 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) Sheet http://www.adnas.com/role/STOCKOPTIONSANDWARRANTSTables STOCK OPTIONS AND WARRANTS (Tables) Tables http://www.adnas.com/role/STOCKOPTIONSANDWARRANTS 18 false false R19.htm 019 - Disclosure - GEOGRAPHIC AREA INFORMATION (Tables) Sheet http://www.adnas.com/role/GEOGRAPHICAREAINFORMATIONTables GEOGRAPHIC AREA INFORMATION (Tables) Tables http://www.adnas.com/role/GeographicAreaInformation 19 false false R20.htm 020 - Disclosure - SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) Sheet http://www.adnas.com/role/SummaryOfAccountingPoliciesSummaryOfPotentialStockIssuancesUnderVariousOptionsAndWarrantsDetails SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) Details 20 false false R21.htm 021 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) Sheet http://www.adnas.com/role/SummaryOfAccountingPoliciesDetailTextuals SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) Details http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESTables 21 false false R22.htm 022 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailTextuals1 SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) Details http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESTables 22 false false R23.htm 023 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) Sheet http://www.adnas.com/role/LiquidityAndManagementSPlanDetailTextuals LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) Details http://www.adnas.com/role/LiquidityAndManagementSPlan 23 false false R24.htm 024 - Disclosure - INVENTORIES (Details) Sheet http://www.adnas.com/role/INVENTORIESDetails INVENTORIES (Details) Details http://www.adnas.com/role/INVENTORIESTables 24 false false R25.htm 025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) Sheet http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESSummaryOfAccountsPayableAndAccruedLiabilitiesDetails ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) Details 25 false false R26.htm 026 - Disclosure - CAPITAL STOCK (Detail Textuals) Sheet http://www.adnas.com/role/CapitalStockDetailTextuals CAPITAL STOCK (Detail Textuals) Details http://www.adnas.com/role/CAPITALSTOCK 26 false false R27.htm 027 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsTransactionsInvolvingWarrantsDetails STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) Details 27 false false R28.htm 028 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees and consultants (Details 1) Sheet http://www.adnas.com/role/STOCKOPTIONSANDWARRANTSTransactionsInvolvingStockOptionsIssuedToEmployeesAndConsultantsDetails1 STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees and consultants (Details 1) Details 28 false false R29.htm 029 - Disclosure - STOCK OPTIONS AND WARRANTS - Fair value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details 2) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsSummaryOfValueOfOptionsGrantedUsingBlackScholesOptionPricingModelWithWeightedAverageAssumptionsDetails STOCK OPTIONS AND WARRANTS - Fair value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details 2) Details 29 false false R30.htm 030 - Disclosure - STOCK OPTIONS AND WARRANTS (Detail Textuals) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsEmployeeStockOptionsDetailTextuals STOCK OPTIONS AND WARRANTS (Detail Textuals) Details http://www.adnas.com/role/STOCKOPTIONSANDWARRANTSTables 30 false false R31.htm 031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals) Sheet http://www.adnas.com/role/COMMITMENTSANDCONTINGENCIESDetailTextuals COMMITMENTS AND CONTINGENCIES (Detail Textuals) Details http://www.adnas.com/role/COMMITMENTSANDCONTINGENCIES 31 false false R32.htm 032 - Disclosure - GEOGRAPHIC AREA INFORMATION (Details) Sheet http://www.adnas.com/role/GEOGRAPHICAREAINFORMATIONDetails GEOGRAPHIC AREA INFORMATION (Details) Details http://www.adnas.com/role/GEOGRAPHICAREAINFORMATIONTables 32 false false All Reports Book All Reports apdn-20180331.xml apdn-20180331.xsd apdn-20180331_cal.xml apdn-20180331_def.xml apdn-20180331_lab.xml apdn-20180331_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/country/2017-01-31 true true ZIP 50 0001144204-18-025076-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-18-025076-xbrl.zip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end